(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 May 2008 (29.05.2008)

PCT

(10) International Publication Number
WO 2008/063505 A1

(51) International Patent Classification:
A01N 43/04 (2006.01) *A61K 31/70* (2006.01)
A01N 43/50 (2006.01)

(21) International Application Number:
PCT/US2007/023854

(22) International Filing Date:
13 November 2007 (13.11.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/858,732 13 November 2006 (13.11.2006) US
60/873,175 5 December 2006 (05.12.2006) US

(71) Applicant *(for all designated States except US)*: **INTRACELLULAR THERAPIES, INC.** [US/US]; 3960 Broadway, New York, NY 10032 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MATES, Sharon** [US/US]; 3960 Broadway, New York, NY 10032 (US). **FIENBERG, Allen, A.** [US/US]; 3960 Broadway, New York, NY 10032 (US).

(74) Agents: **YANG, Arthur** et al.; Hoxie & Associates LLC., 75 Main Street, Suite 301, Millburn, NJ 07041 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) Title: ORGANIC COMPOUNDS

(57) Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment and/or prophyalxis of narcolepsy.

WO 2008/063505 A1

ORGANIC COMPOUNDS

This application claims priority from U.S. Provisional Application No. 60/858,732, filed on November 13, 2006, and U.S. Provisional Application No. 60/873,175, filed on December 5, 2006, the contents of both of which are hereby incorporated by reference in their entirety.

TECHNICAL FIELD

[0001] The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor intracellular pathway, specifically for the treatment of narcolepsy.

BACKGROUND OF THE INVENTION

[0002] Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles normally. At various times throughout the day, people with narcolepsy experience fleeting urges to sleep. If the urge becomes overwhelming, patients fall asleep for periods lasting from a few seconds to several minutes. In rare cases, some people may remain asleep for an hour or longer.

[0003] Narcoleptic sleep episodes can occur at any time, often without warning, and may be quite dangerous if patients are driving or operating machinery. In addition to daytime sleepiness, patients may experience cataplexy, or the sudden loss of voluntary muscle tone; vivid hallucinations during sleep onset or upon awakening; brief episodes of total paralysis at the beginning or end of sleep; and/or automatic behavior, such as talking or performing routine activities during a sleep episode but having no memory of these activities upon waking. Most patients also experience frequent awakenings during nighttime sleep. For these reasons, narcolepsy is considered to be a disorder of the normal boundaries between the sleeping and waking states.

[0004] Eleven families of phosphodiesterases (PDEs) have been identified but only PDEs in Family I, the Ca^{2+}-calmodulin-dependent phosphodiesterases (CaM-

PDEs), have been shown to mediate the calcium and cyclic nucleotide (e.g. cAMP and cGMP) signaling pathways. The three known CaM-PDE genes, PDE1A, PDE1B, and PDE1C, are all expressed in central nervous system tissue. PDE1A is expressed throughout the brain with higher levels of expression in the CA1 to CA3 layers of the hippocampus and cerebellum and at a low level in the striatum. PDE1A is also expressed in the lung and heart. PDE1B is predominately expressed in the striatum, dentate gyrus, olfactory tract and cerebellum, and its expression correlates with brain regions having high levels of dopaminergic innervation. Although PDE1B is primarily expressed in the central nervous system, it may be detected in the heart. PDE1C is primarily expressed in olfactory epithelium, cerebellar granule cells, and striatum. PDE1C is also expressed in the heart and vascular smooth muscle.

[0005] Cyclic nucleotide phosphodiesterases downregulate intracellular cAMP and cGMP signaling by hydrolyzing these cyclic nucleotides to their respective inactive 5'-monophosphates (5'AMP and 5'GMP). CaM-PDEs play a critical role in mediating signal transduction in brain cells, particularly within an area of the brain known as the basal ganglia or striatum. For example, NMDA-type glutamate receptor activation and/or dopamine D2 receptor activation result in increased intracellular calcium concentrations, leading to activation of effectors such as calmodulin-dependent kinase II (CaMKII) and calcineurin and to activation of CaM-PDEs, resulting in reduced cAMP and cGMP. Dopamine D1 receptor activation, on the other hand, leads to activation of calcium dependent nucleotide cyclases, resulting in increased cAMP and cGMP. These cyclic nucleotides in turn activate protein kinase A (PKA; cAMP-dependent protein kinase) and/or protein kinase G (PKG; cGMP-dependent protein kinase) that phosphorylate downstream signal transduction pathway elements such as DARPP-32 (dopamine and cAMP-regulated phosphoprotein) and cAMP responsive element binding protein (CREB).

[0006] CaM-PDEs can therefore affect dopamine-regulated and other intracellular signaling pathways in the basal ganglia (striatum), including but not limited to nitric oxide, noradrenergic, neurotensin, CCK, VIP, serotonin, glutamate (e.g., NMDA receptor, AMPA receptor), GABA, acetylcholine, adenosine (e.g., A2A

receptor), cannabinoid receptor, natriuretic peptide (e.g., ANP, BNP, CNP) and endorphin intracellular signaling pathways.

[0007] Phosphodiesterase (PDE) activity, in particular, phosphodiesterase 1 (PDE1) activity, functions in brain tissue as a regulator of locomotor activity and learning and memory. PDE1 is a therapeutic target for regulation of intracellular signaling pathways, preferably in the nervous system, including but not limited to a dopamine D1 receptor, dopamine D2 receptor, nitric oxide, noradrenergic, neurotensin, CCK, VIP, serotonin, glutamate (e.g., NMDA receptor, AMPA receptor), GABA, acetylcholine, adenosine (e.g., A2A receptor), cannabinoid receptor, natriuretic peptide (e.g., ANP, BNP, CNP) or endorphin intracellular signaling pathway. For example, inhibition of PDE1B may potentiate the effect of a dopamine D1 agonist by protecting cGMP and cAMP from degradation, and similarly inhibit dopamine D2 receptor signaling pathways, by inhibiting PDE1 activity. PDE1 inhibitors are therefore potentially useful in diseases characterized by reduced dopamine D1 receptor signaling activity. See generally, WO 03/020702.

[0008] EP 0201188 and EP 0911333, the contents of which are incorporated herein by reference, disclose certain 1,3,5,-substituted, 6,7-dihydro-1H-pyrazolo[4,3-*d*]pyrimidin-7-one compounds, claimed to be useful for treatment of cardiovascular disease, erectile dysfunction, and other disorders. These compounds are not, however, taught or suggested to be useful for the treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, particularly diseases relating to sleep disorders such as narcolepsy. PCT/US2006/33179, the contents of which are incorporated herein by reference, discloses the use of 1,3,5,-substituted, 6,7-dihydro-1H-pyrazolo[4,3-*d*]pyrimidin-7-one compounds for treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, but does not specifically disclose the use of such compounds in the treatment or prophylaxis of narcolepsy. PCT/US2006/022066, the contents of which are incorporated herein by reference, discloses PDE1 inhibitors which are 7,8-dihydro-[1*H* or 2*H*]-imidazo[1,2-*a*]pyrazolo[4,3-*e*]pyrimidin-4(5*H*)-ones or 7,8,9-trihydro-[1*H* or 2*H*]-pyrimido [1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-ones, but does not specifically disclose their use for the treatment or propylaxis of narcolepsy. WO 03/042216, U.S. 5,939,419, EP 0 538

332, U.S. 5,393,755, U.S. 6,969,719 B2, Xia et al., *J. Med. Chem.* (1997), 40, 4372-4377 and Ahn et al., *J. Med. Chem.* (1997), 40, 2196-2210, the contents of all of which are incorporated herein by reference, disclose PDE1 cGMP phosphodiesterase inhibitors which are substituted pyrazolo[3,4-d]pyrimidine, pyrimido[2,1-b]purin-4-one and imidazo[2,1-b]purin-4-one analogues useful for the treatment of hypertensive, cardiovascular, sexual dysfunction and other cGMP-PDEV related disorders, but do not specifically disclose their use for the treatment or propylaxis of narcolepsy.

SUMMARY OF THE INVENTION

[0009] The invention provides a new method of treatment or prophylaxis for narcolepsy comprising administering an effective amount of a phosphodiesterase-1 (PDE1) inhibitor to a patient in need thereof. PDE1 inhibitors include, for example, 7,8-dihydro-[1*H* or 2*H*]-imidazo[1,2-*a*]pyrazolo[4,3-*e*]pyrimidin-4(5*H*)-ones or 7,8,9-trihydro-[1*H* or 2*H*]-pyrimido [1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-ones, substituted at the 1 or 2 position with C_{2-9} alkyl or C_{3-9} cycloalkyl, or optionally substituted heteroarylalkyl or substituted arylalkyl, in free, salt or prodrug form (hereinafter a PDE 1 Inhibitor, e.g., as described below) or a 1,3,5-substituted 6,7-dihydro-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-one, in free, salt or prodrug form (also included in PDE 1 Inhibitors, e.g., as described below), to a patient in need thereof.

[0010] PDE1 inhibitors also include, for example, substituted imidazo[2,1-b]purin-4-one, e.g., (6aR,9aS)-2-(biphenyl-4-ylmethyl)-5,6a,7,8,9,9a-hexahydro-5-methyl-3(phenylmethyl)-cyclopent-[4,5]imidazo-[2,1-b]purin-4(3*H*)-one, (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-2,3-bis(phenylmethyl)cyclopent-[4,5]imidazo-[2,1-b]purin-4(3*H*)-one, 5'-methyl-2',3'-bis(phenylmethyl)spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-one, or 5'-methyl-2'-(biphenylylmethyl)-3'-(phenylmethyl)spiro[cyclopentane-1,7'(8'H)-[3*H*]imidazo[2,1-b]purin]-4'(5'H)-one as described in Ahn et al., *J. Med. Chem.* (1997), 40, 2196-2210 (hereinafter a PDE 1 Inhibitor, e.g., as described below). These compounds are found to selectively inhibit phosphodiesterase 1 (PDE1) activity, especially PDE1B activity, and to be useful in the treatment and prophylaxis of narcolepsy. These compounds are found to selectively

inhibit phosphodiesterase 1 (PDE1) activity, especially PDE1B activity, and to be useful in the treatment and prophylaxis of narcolepsy.

DETAILED DESCRIPTION OF THE INVENTION

Compounds for use in the methods of the invention

[0011] Preferably, the PDE 1 Inhibitors for use in the methods of treatment described herein are a 7,8-dihydro-[1*H* or 2*H*]-imidazo[1,2-*a*]pyrazolo[4,3-*e*]pyrimidin-4(5*H*)-ones or 7,8,9-trihydro-[1*H* or 2*H*]-pyrimido [1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-ones, of formula I



Formula I

wherein

(i) R_1 is H or C_{1-4} alkyl (e.g., methyl);

(ii) R_4 is H or C_{1-4} alkyl and R_2 and R_3 are, independently, H or C_{1-4} alkyl (e.g., R_2 and R_3 are both methyl, or R_2 is H and R_3 is isopropyl), aryl, heteroaryl, (optionally hetero)arylalkoxy, or (optionally hetero)arylalkyl;

or

R_2 is H and R_3 and R_4 together form a di-, tri- or tetramethylene bridge

(pref. wherein the R_3 and R_4 together have the *cis* configuration, e.g., where the carbons carrying R_3 and R_4 have the R and S configurations, respectively);

(iii) R_5 is a substituted heteroarylalkyl, e.g., substituted with haloalkyl

or

R_5 is attached to one of the nitrogen atoms on the pyrazolo portion of Formula I and is a moiety of Formula Q



Formula Q

wherein X, Y and Z are, independently, N or C, and R_8, R_9, R_{11} and R_{12} are independently H or halogen (e.g., Cl or F), and R_{10} is halogen, alkyl, cycloalkyl, haloalkyl (e.g., trifluoromethyl), aryl (e.g., phenyl), heteroaryl (e.g., pyridyl (for example pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl)), diazolyl, triazolyl, tetrazolyl, arylcarbonyl (e.g., benzoyl), alkylsulfonyl (e.g., methylsulfonyl), heteroarylcarbonyl, or alkoxycarbonyl; provided that when X, Y, or Z is nitrogen, R_8, R_9, or R_{10}, respectively, is not present; and

(iv) R_6 is H, alkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), arylamino (e.g., phenylamino), heterarylamino, N,N-dialkylamino, N,N-diarylamino, or N-aryl-N-(arylakyl)amino (e.g., N-phenyl-N-(1,1'-biphen-4-ylmethyl)amino); and

(v) n=0 or 1;

(vi) when n=1, **A** is $-C(R_{13}R_{14})-$

wherein R_{13} and R_{14}, are, independently, H or C_{1-4} alkyl, aryl, heteroaryl, (optionally hetero)arylalkoxy or (optionally hetero)arylalkyl;

in free, salt or prodrug form, including its enatiomers, diasterisomers and racemates.

[0012] The invention further provides the use of PDE 1 Inhibitors of Formula I as follows:

1.1 Formula I wherein R_1 is methyl and n=0;

1.2 Formula I or 1.1 wherein R_4 is H or C_{1-4} alkyl and at least one of R_2 and R_3 is lower alkyl, such that when the carbon carrying R_3 is chiral, it has the R configuration, e.g., wherein both R_2 and R_3 are methyl, or wherein one is hydrogen and the other isopropyl;

1.3 Formula I or 1.1 wherein R_4 is H and at least one of R_2 and R_3 is arylalkoxy;

1.4 Formula I wherein R_1 is methyl, R_2, R_3, and R_4 are H, n=1, and R_{13} and R_{14} are, independently, H or C_{1-4} alkyl (e.g., methyl or isopropyl);

1.5 Formula I or 1.1 wherein R_2 is H and R_3 and R_4 together form a tri- or tetramethylene bridge, having the *cis* configuration, preferably wherein the carbons carrying R_3 and R_4 have the R and S configurations respectively;

1.6 Formula I, 1.1 or 1.5 wherein R_5 is a substituted heteroarylmethyl, e.g., para-substituted with haloalkyl;

1.7 Formula I, 1.1, 1.2, 1.3, 1.4 or 1.5 wherein R_5 is a moiety of Formula Q wherein R_8, R_9, R_{11}, and R_{12} are H and R_{10} is phenyl;

1.8 Formula I, 1.1, 1.2, 1.3, 1.4 or 1.5 wherein R_5 is a moiety of Formula Q wherein R_8, R_9, R_{11}, and R_{12} are H and R_{10} is pyridyl or thiadiazolyl;

1.9 Formula I, 1.1, 1.2, 1.3, 1.4 or 1.5 wherein R_5 is a moiety of Formula Q wherein R_8, R_9, R_{11}, and R_{12} are, independently, H or halogen, and R_{10} is haloalkyl;

1.10 Formula I, 1.1, 1.2, 1.3, 1.4 or 1.5 wherein R_5 is a moiety of Formula Q wherein R_8, R_9, R_{11}, and R_{12} are, independently, H, and R_{10} is alkyl sulfonyl;

1.11 any of the preceding formulae wherein R_5 is attached to the 2-position nitrogen on the pyrazolo ring;

1.12 any of the preceding formulae wherein R_6 is benzyl;

1.13 any of the preceding formulae wherein R_6 is phenylamino or phenylalkylamino (e.g., benzylamino);

1.14 any of the preceding formulae wherein R_6 is phenylamino;

1.15 any of the preceding formulae wherein X, Y, and Z are all C;

1.16 any of the preceding formulae wherein X, Y, and Z are all C and R_{10} is phenyl or 2-pyridyl; and/or

1.17 any of the preceding formulae wherein the compounds inhibit phosphodiesterase-mediated (e.g., PDE1-mediated, especially PDE1B-mediated) hydrolysis of cGMP, e.g., with an IC_{50} of less than 1μM, preferably less than 25 nM in an immobilized-metal affinity particle reagent PDE assay, for example, as described in Example 1;

in free or salt form.

[0013] For example, the PDE 1 Inhibitors include 7,8-dihydro-[1*H* or 2*H*]-imidazo[1,2-*a*]pyrazolo[4,3-*e*]pyrimidin-4(5*H*)-ones of Formula Ia



Formula Ia

wherein

(i) R_1 is H or C_{1-4} alkyl [e.g., methyl];

(ii) R_4 is H and R_2 and R_3 are, independently, H or C_{1-4} alkyl [e.g., R_2 and R_3 are both methyl, or R_2 is H and R_3 is isopropyl], aryl, or arylalkyl;

or R_2 is H and R_3 and R_4 together form a di-, tri- or tetramethylene bridge [pref. wherein the R_3 and R_4 have the *cis* configuration, e.g., where the carbons carrying R_3 and R_4 have the R and S configurations respectively];

(iii) R_5 is attached to one of the nitrogen atoms on the pyrazolo portion of formula Ia and is a substituted benzyl of formula Qa



Formula Qa

wherein R_8, R_9, R_{11} and R_{12} are independently H or halogen (e.g., Cl or F); and R_{10} is halogen, alkyl, cycloalkyl, haloalkyl (e.g., trifluoromethyl), aryl (e.g., phenyl), heteroaryl (e.g., pyridyl (for example pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl)), arylcarbonyl (e.g., benzoyl), alkyl sulfonyl or heteroarylcarbonyl; and

(iv) R_6 is H, alkyl, aryl, heteroaryl, arylalkyl [e.g., benzyl], arylamino [e.g., phenylamino], heteroarylamino, arylalkylamino, N,N-dialkylamino, N,N-diarylamino, or N-aryl-N-(arylalkyl)amino [e.g. N-phenyl-N-(1,1'-biphen-4-ylmethyl)amino];

in free, salt or prodrug form.

[0014] The invention further provides the use of PDE 1 Inhibitors of Formula Ia as follows:

2.1: Formula Ia wherein R_1 is methyl;

2.2: Formula Ia or 2.1 wherein R_4 is H and at least one of R_2 and R_3 is lower alkyl, such that when the carbon carrying R_3 is chiral, it has the R configuration, e.g., wherein both R_2 and R_3 are methyl, or wherein one is hydrogen and the other isopropyl;

2.3: Formula Ia or 2.1 wherein R_2 is H and R_3 and R_4 together form a tri- or tetramethylene bridge, having the *cis* configuration, preferably wherein the carbons carrying R_3 and R_4 have the R and S configurations respectively;

2.4: Formula Ia, 2.1, 2.2 or 2.3 wherein R_5 is a moiety of formula Qa wherein R_8, R_9, R_{11}, and R_{12} are H and R_{10} is phenyl;

2.5: Formula Ia, 2.1, 2.2, or 2.3 wherein R_5 is a moiety of formula Qa wherein R_8, R_9, R_{11}, and R_{12} are H and R_{10} is pyridyl or thiadiazolyl;

2.6: Formula Ia, 2.1, 2.2, 2.3, 2.4, or 2.5 wherein R_5 is attached to the 2-position nitrogen on the pyrazolo ring;

2.7: Formula Ia, 2.1, 2.2, 2.3, 2.4, 2.5 or 2.6 wherein R_6 is benzyl;

2.8: Formula Ia, 2.1, 2.2, 2.3, 2.4, 2.5 or 2.6 wherein R_6 is phenylamino or phenylalkylamino (e.g., benzylamino); and/or

2.9: Formula Ia, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, or 2.8 wherein the compounds inhibit phosphodiesterase-mediated (e.g., PDE1-mediated, especially PDE1B-mediated) hydrolysis of cGMP, e.g., with an IC_{50} of less than 1μM, preferably less than 25 nM in an immobilized-metal affinity particle reagent PDE assay, for example, as described in Example 1;

in free or salt form.

[0015] In an another embodiment, the PDE 1 Inhibitors are compounds of Formula I wherein

(i) R_1 is methyl;

(ii) R_2, R_3 and R_4 are H;

(iii) n=1 and R_a and R_b are, independently, H or methyl;

(iv) R_5 is a moiety of Formula Q wherein R_8, R_9, R_{11} and R_{12} are H and R_{10} is phenyl, pyridyl (for example pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl);

(v) R_6 is benzyl, phenylamino or benzylamino;

in free or salt form.

[0016] In another embodiment, the PDE 1 Inhibitors are compounds of Formula I wherein

(i) R_1 is methyl;

(ii) n=0;

(iii) R_2 is H and R_3 and R_4 together form a tri-or tetra-methylene bridge [pref. with the carbons carrying R_3 and R_4 having the R and S configuration respectively]; or at least one of R_2 and R_3 is methyl, isopropyl or arylalkoxy and R_4 is H; or R_2 and R_3 are H and R_4 is a C_{1-4} alkyl;

(iv) R_5 is a substituted heteroarylmethyl, e.g., para-substituted with haloalkyl; or

R_5 is a moiety of Formula Q wherein R_8, R_9, R_{11} and R_{12} are H or halogen and R_{10} is haloalkyl, phenyl, pyridyl (for example pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl); and

(v) R_6 is benzyl, phenylamino or benzylamino;

in free or salt form.

[0017] In another embodiment, the PDE 1 Inhibitors are compounds of Formula Ia wherein

(i) R_1 is methyl;

(ii) R_2 is H and R_3 and R_4 together form a tri- or tetra-methylene bridge [pref. with the carbons carrying R_3 and R_4 having the R and S configuration respectively]; or R_2 and R_3 are each methyl and R_4 is H; or R_2 and R_4 are H and R_3 is isopropyl [pref. the carbon carrying R_3 having the R configuration];

(iii) R_5 is a moiety of Formula Qa wherein R_8, R_9, R_{11}, and R_{12} are H and R_{10} is haloalkyl, phenyl, pyridyl (for example pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl); and

(iv) R_6 is benzyl, phenylamino or benzylamino;

in free or salt form.

[0018] In another embodiment, the PDE 1 Inhibitors are compounds of Formula Ia selected from the following:



Compound 1



Compound 2

[0019] For example, PDE 1 Inhibitors include compounds according to Formulae II, III and IV.



Formula II

wherein

R_a and R_b are, independently, H or C_{1-4} alkyl;

R_6 is phenylamino or benzylamino;

R_{10} is phenyl, pyridyl (for example pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl);

in free or salt form.



Formula III

wherein

R_2 is H and R_3 and R_4 together form a tri- or tetra-methylene bridge [pref. with the carbons carrying R_3 and R_4 having the R and S configuration respectively]; or at least one of R_2 and R_3 is methyl, isopropyl or arylalkoxy and R_4 is H; or R_2 and R_3 are H and R_4 is a C_{1-4} alkyl;

R_6 is phenylamino or benzylamino;

R_{10} is haloalkyl, phenyl, pyridyl (for example pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl);

in free or salt form.



Formula IV

wherein

R_2 is H and R_3 and R_4 together form a tri- or tetra-methylene bridge [pref. with the carbons carrying R_3 and R_4 having the R and S configuration respectively]; or at least one of R_2 and R_3 is methyl, isopropyl or arylalkoxy and R_4 is H; or R_2 and R_3 are H and R_4 is a C_{1-4} alkyl;

R_6 is phenylamino or benzylamino;

R_{10} is phenyl, pyridyl (for example pyrid-2-yl), or thiadiazolyl (e.g., 1,2,3-thiadiazol-4-yl);

in free or salt form.

[0020] PDE 1 Inhibitors used in the method disclosed herein also include compounds according to Formula V:



Formula V

wherein

R_2 is H and R_3 and R_4 together form a tri- or tetra-methylene bridge [pref. with the carbons carrying R_3 and R_4 having the R and S configuration respectively]; or R_2 and R_3 are each methyl and R_4 is H; or R_2 and R_4 are H and R_3 is isopropyl [pref. the carbon carrying R_3 having the R configuration];

R_6 is phenylamino or benzylamino;

R_{10} is phenyl, pyridyl, or thiadiazolyl;

in free or salt form.

In a preferred embodiment, the PDE 1 Inhibitors for use in the methods of treatment described herein are a 1,3,5-substituted 6,7-dihydro-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-one, of formula VI



Formula VI

wherein

R_a is methyl or C_2-C_6 alkyl;

R_1 is H or C_1-C_4 alkyl;

each of R_2 and R_3 is independently selected from H and C_1-C_4 alkyl, or R_2 is H or C_1-C_4 alkyl and R_3 is OH, C_2-C_4 alkanoyloxy or fluoro, or R_2 and R_3 when taken together represent C_2-C_6 alkylene, or R_2 and R_3 when taken together with the carbon atom to which they are attached represent a carbonyl group;

Ar is either (a)



wherein

each of R_4, R_5 and R_6 is independently selected from

H
C_1-C_4 alkyl,
C_1-C_4 alkoxy,
C_1-C_4 alkoxy-Z-,
halo,
halo(C_1-C_4)alkyl,
phenoxy, optionally substituted by up to three substitutents each of which substitutent is independently selected from halo, C_{1-4} alkyl, and C_1-C_4 alkoxy,
nitro,
hydroxy,
hydroxy-Z-,
C_2-C_4 alkanoyl,
amino,
amino-Z-,
(C_1-C_4 alkyl)NH,

$(C_1\text{-}C_4\ alkyl)_2N$-,

$(C_1\text{-}C_4\ alkyl)NH$-Z-,

$(C_1\text{-}C_4\ alkyl)_2N$-Z-,

-COOH,

-Z-COOH,

$-COO(C_1\text{-}C_4\ alkyl)$,

$-Z\text{-}COO(C_1\text{-}C_4\ alkyl)$

$C_1\text{-}C_4$ alkanesulphonamido,

$C_1\text{-}C_4$ alkanesulphonamido-Z-,

$halo(C_1\text{-}C_4)$alkanesulphonamido,

$halo(C_1\text{-}C_4)$alkanesulphonamido-Z-,

$C_1\text{-}C_4$ alkanamido,

$C_1\text{-}C_4$ alkanamido-Z-,

HOOC-Z-NH-,

HOOC-Z-NH-Z-,

$(C_1\text{-}C_4\ alkyl)OOC$-Z-NH-,

$(C_1\text{-}C_4\ alkyl)OOC$-Z-NH-Z-,

$C_1\text{-}C_4\ alkyl\text{-}NH\text{-}SO_2\text{-}NH$-,

$C_1\text{-}C_4\ alkyl\text{-}NH\text{-}SO_2\text{-}NH$-Z-,

$(C_1\text{-}C_4\ alkyl)_2\text{-}N\text{-}SO_2\text{-}NH$-,

$(C_1\text{-}C_4\ alkyl)_2\text{-}N\text{-}SO_2\text{-}NH$-Z-,

$C_1\text{-}C_4$ alkoxy CH=CH-Z-CONH-,

$C_1\text{-}C_4$ alkoxy CH=CHCONH

$C_1\text{-}C_4\ alkyl\text{-}SO_2\text{-}N(C_1\text{-}C_4\ alkyl)$-,

$C_1\text{-}C_4\ alkyl\text{-}SO_2\text{-}N(C_1\text{-}C_4\ alkyl)$-Z-,

$(C_1\text{-}C_4\ alkyl)NH\text{-}Z\text{-}SO_2\text{-}NH$-,

$(C_1\text{-}C_4\ alkyl)_2N\text{-}Z\text{-}SO_2\text{-}NH$-,

$(C_1\text{-}C_4\ alkyl)NH\text{-}Z\text{-}SO_2\text{-}NH$-Z-,

$(C_1\text{-}C_4\ alkyl)_2N\text{-}Z\text{-}SO_2\text{-}NH$-Z-,

benzenesulphonamido, optionally ring substituted by up to three substitutents each of which is independently selected from halo, C_{1-4} alkyl, and C_1-C_4 alkoxy,

C_1-C_4 alkanoyl-N(C_1-C_4 alkyl)-,

C_1-C_4 alkanoyl-N(C_1-C_4 alkyl)-Z-,

C_1-C_4 alkoxycarbonyl-$CH(CH_2OH)NHSO_2$-,

$-SO_3H$,

$-SO_2NH_2$,

H_2NOC-$CH(CH_2OH)$-$NHSO_2$-,

HOOC-Z-O-, and

(C_1-C_4 alkyl)OOC-Z-O-,

or optionally one of R_4, R_5 and R_6 is a G-Het group and wherein the others of R_4, R_5 and R_6 are independently selected from the R_4, R_5 and R_6 substitutents listed above;

Z is C_1-C_4 alkylene,

G is a direct link, Z, O, $-SO_2NH$-, SO_2, or -Z-N(C_1-C_4 alkyl)SO_2-,

Het is a 5- or 6-membered heterocyclic group containing 1, 2, 3 or 4 nitrogen heteroatoms; or 1 or 2 nitrogen heteroatoms and 1 sulphur heteroatom or 1 oxygen heteroatom; or the heterocyclic group is furanyl or thiophenyl; wherein the Het group is saturated or partially or fully unsaturated and optionally substituted by up to 3 substitutents, wherein each substitutent is independently selected from C_1-C_4 alkyl, oxo, hydroxy, halo, and halo(C_1-C_4) alkyl;

or (b) any one of the following bicyclic groups:

benzodioxolanyl,

benzodioxanyl,

benzimidazolyl,

quinolinyl,
indolyl,
quinazolinyl,
isoquinolinyl,
benzotriazolyl,
benzofuranyl,
benzothiophenyl,
quinoxalinyl, or
phthalizinyl,

wherein said bicyclic Ar groups are linked to the neighbouring -C(R_2R_3)- group *via* the benzo ring portion,

and wherein the heterocyclic portion of said bicyclic Ar group is optionally partially or fully saturated, said group being optionally substituted by one or more of C_1-C_4 alkyl, halo, hydroxy, oxo, amino, and C_1-C_4 alkoxy;

or a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable solvate of the compound or the salt.

[0021] For example, PDE 1 Inhibitors for use in the present invention include 1,3,5,-substituted, 6,7-dihydro-1H-pyrazolo[4,3-*d*]pyrimidin-7-one, in free or pharmaceutically acceptable salt form, particularly compounds of Formula VI or the following formulae:

3.2 Of Formula VI wherein R_a is a C_{2-5} alkyl group;

3.3 Of Formula VI wherein R_a is a C_{2-4} alkyl group;

3.4 Of Formula VI wherein R_a is a C_3 alkyl group;

3.5 Of Formula VI wherein R_a is methyl;

3.6 Of Formula VI, 3.2, 3.3, 3.4 or 3.5 wherein R_1 is a C_{1-6} alkyl group;

3.7 Of any of the preceding formulae wherein R_1 is a C_{1-3} alkyl group;

3.8 Of any of the preceding formulae wherein R_1 is a methyl group;

3.9 Of any of the preceding formulae wherein R_2 is H;

3.10 Of any of the preceding formulae wherein R_3 is H;

3.11 Of any of the preceding formulae wherein R_4, R_5 and R_6 are independently selected from H, $(C_{1-4}$ alkyl$)_2N$-, C_{1-4} alkanesulphonamido and benzenesulphonamido;

3.12 Of any of the preceding formulae wherein R_4, R_5 and R_6 are independently selected from H, diethylamino, methanesulphonamido and benzenesulphonamido;

3.13 Of any of the preceding formulae wherein Ar is 4-diethylaminophenyl;

3.14 Of any of the preceding formulae wherein Ar is 2-methanesulphonamidophenyl;

3.15 Of any of the preceding formulae wherein Ar is 4-benzenesulphonamidophenyl;

3.16 Of any of the preceding formulae wherein one of R_4, R_5 and R_6 is $(C_{1-4}$ alkyl$)_2N$- and wherein the other two of R_4, R_5 and R_6 are H.

3.17 Of any of the preceding formulae wherein one of R_4, R_5 and R_6 is diethylamino and wherein the other two of R_4, R_5 and R_6 are H.

3.18 Of any of the preceding formulae wherein R_a is methyl;

3.19 Of any of the preceding formulae wherein R_a is C_2-C_6 alkyl;

3.20 Of any of the preceding formulae wherein the compound is selected from the following:


O
Me
HN
N
N
Et
N
N
Et
Me


O
Me
SO2
NH
Me
HN
N
N
N
Me


O
Me
HN
N
N
SO2
HN
N
Me

3.21 Of any of the preceding formulae wherein the compound is



in free or salt form;

3.22 A compound which is a 1,3,5,-substituted, 6,7-dihydro-1H-pyrazolo[4,3-*d*]pyrimidin-7-one, in free or pharmaceutically acceptable salt form, e.g. a compound of Formula VI or according to any of formulae 3.2 – 3.21, wherein the compound inhibits phosphodiesterase-mediated (e.g., PDE1-mediated, especially PDE1B-mediated) hydrolysis of cGMP, e.g., with an IC_{50} of less than 1μM, preferably less than 25 nM in an immobilized-metal affinity particle reagent PDE assay, for example, as described in Example 1 below.

[0022] In another embodiment, the PDE 1 Inhibitors for use in the methods of treatment described herein are substituted (imidazo, pryimido or diazepino)[2,1-b]purin-4-ones of Formula VIIa or VIIb:



Formula VIIa



Formula VIIb

in free, salt or prodrug form, including its enatiomers, diasterisomers and racemates, wherein:

i) q = 0, 1 or 2;

ii) R^1, R^a, R^b, R^c and R^d are each independently H, alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups,

wherein each alkyl group of R^1, R^a, R^b, R^c and R^d is independently unsubstituted or substituted with 1 to 5 independently selected R^3 moieties which can be the same or different, each R^3 moiety being independently selected from the group consisting of hydroxy, alkoxy, cycloalkoxy, aryloxy, alkylthio, arylthio, aryl, haloaryl, heteroaryl, cycloalkyl, heterocycloalkyl, amino, alkylamino, dialkylamino, cycloalkylamino and heterocycloalkylamino groups;

wherein each of the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups of R^1, R^a, R^b, R^c and R^d is independently unsubstituted or substituted with 1 to 5 independently selected R^4 moieties which can be the same or different, each R^4 moiety being independently selected from the group consisting of: halo, optionally substituted aryl (e.g., phenyl, chlorophenyl, methoxyphenyl), heteroaryl (e.g., pyridyl, pyrrolyl), nitro, cyano, haloalkyl, haloalkoxy, alkyl, alkoxy, cycloalkyl, heterocycloalkyl (e.g., pyrolidinyl, morpholin-4-yl, pyrrol-1-yl), cycloalkylalkyl, amino, alkylamino, dialkylamino, -OCF_3, acyloxy, -

OR^8, $-C(O)R^9$, $-C(O)OR^8$, $-NR^{10}C(O)R^9$, $-NR^{10}C(O)OR^8$,- $NR^{10}S(O)_2R^9$, - $S(O)_{0-2}R^9$ groups, carbonyl when two hydrogens attached to the same carbon atom of the cycloalkyl or heterocycloalkyl group of R' are substituted, and $=CR^8R^9$ when two hydrogens attached to the same carbon atom of the cycloalkyl or heterocycloalkyl groups of R^1 are substituted,

wherein each of the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups of the $R^3$and R^4 moieties above is independently unsubstituted or substituted with 1 to 5 independently selected R^{12} moieties which can be the same or different, each R^{12} moiety being independently selected from the group consisting of: halo, phenyl, nitro, cyano, haloalkyl, haloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, amino, alkylamino, $-OCF_3$, acyloxy, $-OR^8$, $-C(O)R^9$, $-C(O)OR^8$, $-NR^{10}C(O)R^9$, $-NR^{10}C(O)OR^8$,- $NR^{10}S(O)_2R^9$, - $S(O)_{0-2}R^9$ groups, carbonyl when two hydrogens attached to the same carbon atom of the cycloalkyl or heterocycloalkyl group of R^3 or R^4 are substituted, and $=CR^8R^9$ when two hydrogens attached to the same carbon atom of the cycloalkyl or heterocycloalkyl group of R^3 or R^4 are substituted; or

iii) R^a and R^b, together with the carbon to which they are both attached, form a 4- to 7-membered cycloalkyl or heterocycloalkyl ring, and R^c and R^d are each independently H or an alkyl group; or

iv) R^a and R^c, together with the respective carbons to which they are attached, form a 4- to 7-membered cycloalkyl or heterocycloalkyl ring, and R^b and R^d are each independently H or an alkyl group, preferably R^a and R^c together have the *cis* configuration, e.g., where the carbons carrying R^a and R^c have the R and S configurations, respectively;

v) R^2 is H, halo, alkyl, haloalkyl, alkoxy, alkylthio, amino, aminosulfonyl, monoalkylamino, dialkylamino, hydroxyalkylamino, aminoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl or alkylaminocarbonyl group,

wherein each alkyl group of R^2 is independently unsubstituted or substituted with 1 to 5 independently selected R^{13} moieties which can be the same or different, each R^{13} moiety being independently selected from the group consisting of halo, hydroxy, alkoxy, alkyl, aryl (e.g., phenyl, naphthyl) heteroaryl (e.g., 1H-imidazol-2-yl), cycloalkyl, heterocycloalkyl (e.g., pyrolidin-1-yl), amino, monoalkylamino or dialkylamino group,

wherein each aryl group of R^{13} is independently unsubstituted or substituted with 1 to 5 independently selected R^4 moieties which can be the same or different;

vi) Y is H or an alkyl group substituted with (i) an aryl, heteroaryl, cycloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino group, or (ii) an aryl group substituted with from one to three moieties each independently selected from the group consisting of: halo, alkyl, phenyl, hydroxy, alkoxy, phenoxy, amino, monoalkylamino and dialkylamino group;

vii) each R^8 is independently H, alkyl or aryl;

viii) each R^9 is independently H, alkyl, aryl or $-NR^{10}R^{11}$;

ix) each R^{10} is independently H, alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, wherein each alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of R^{10} is unsubstituted or independently substituted with 1 to 5 R^{14} moieties which can be the same or different, each R^{14} moiety being independently selected from the group consisting of: halo, alkyl, aryl, cycloalkyl, $-CF_3$, $-OCF_3$, -CN, $-OR^8$, $-CH_2OR^8$, $-C(O)OR^8$ and $-C(O)NR^8R^8$; and

x) each R^{11} is independently H, alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, wherein each alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of R^{11} is unsubstituted or independently substituted with 1 to 5 R^{14} moieties which can be the same or different.

[0023] The invention further provides the use of PDE 1 Inhibitors of Formula VIIa or VIIb, in free or salt form, as follows:

4.1: Formula VIIa or VIIb, wherein q = 0, 1 or 2;

4.2: Formula VIIa or VIIb, wherein q = 0;

4.3: Formula VIIa or VIIb or 4.1 or 4.2, wherein R^1 is alkyl;

4.4: Formula VIIa or VIIb or 4.1-4.3, wherein R^1 is methyl;

4.5: Formula VIIa or VIIb or 4.1-4.4, wherein R^a and R^c, together with the respective carbons to which they are attached, form a 4- to 7-membered cycloalkyl or heterocycloalkyl ring, and R^b and R^d are each independently H or an alkyl group;

4.6: Formula VIIa or VIIb or 4.1-4.4, wherein R^a and R^c, together with the respective carbons to which they are attached, form a 5-membered heterocycloalkyl ring, and R^b and R^d are each independently H;

4.7: Formula 4.6 wherein R^a and R^c together have a *cis* configuration;

4.8: Formula VIIa or VIIb or 4.1-4.4, wherein R^a and R^b, together with the respective carbons to which they are attached, form a 5-membered heterocycloalkyl ring, and R^c and R^d are each independently H;

4.9: Formula VIIa or VIIb or 4.1-4.7, wherein R^2 is alkyl or haloalkyl;

4.10: Formula VIIa or VIIb or 4.1-4.7, wherein R^2 is biphenyl-4-ylmethyl;

4.11: Formula VIIa or VIIb or 4.1-4.7, wherein R^2 is benzyl;

4.12: Formula VIIa or VIIb or 4.1-4.7, wherein R^2 is cyclopentylmethyl;

4.13: Formula VIIa or VIIb or 4.1-4.7, wherein R^2 is cyclopropylmethyl; and/or

4.14: Formula VIIa or VIIb or 4.1-4.12, wherein Y is benzyl;

4.15: Of any of the preceding formulae wherein the compound is selected from the following:


,

,

,

,


4.16: Of any of the preceding formulae wherein the compound is



in free or salt form;

4.17: A compound which is a substituted imidazo[2,1-b]purin-4-one, in free or pharmaceutically acceptable salt form, e.g. a compound of Formula VIIa or according to any of formulae 4.1 – 4.16, wherein the compound inhibits phosphodiesterase-mediated (e.g., PDE1-mediated, especially PDE1B-mediated) hydrolysis of cGMP, e.g., with an IC_{50} of less than 1μM, preferably less than 25 nM in an immobilized-metal affinity particle reagent PDE assay, for example, as described in Example 1 below.

[0024] Preferably, compounds of Formula VIIa or VIIb are selected from a group consisting of (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-2,3-bis(phenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3*H*)-one, (6aR,9aS)-2-(biphenyl-4-ylmethyl)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3*H*)-one, 5'-methyl-2',3'-bis(phenylmethyl)spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-one and 5'-methyl-2'-(biphenyl-4-ylmethyl)-3'-(phenylmethyl)spiro-[cyclopentane-1,7'(8'H)-[3*H*]imidazo[2,1-b]purin]-4'(5'H)-one, in free or pharmaceutically acceptable salt form.

[0025] In an especially preferred embodiment, compound of Formula VIIa is (6aR,9aS)-2-(biphenyl-4-ylmethyl)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3*H*)-one, in free or salt form.

[0026] The numbering of substituted imidazo[2,1-b]purin-4-one of Formula VIIa or VIIb as described herein is shown below as an example, wherein q = 0:



Formula VIIa



Formula VIIb

wherein q = 1:



Formula VIIa



Formula VIIb

[0027] In another embodiment, the PDE 1 Inhibitors for use in the methods of treatment described herein are Compounds of Formula VIIIa or VIIIb:



Formula VIIIa



Formula VIIIb

in free or salt form, wherein:

- J is oxygen or sulfur,
- R^1 is hydrogen, alkyl or alkyl substituted with aryl or hydroxy;

- R^2 is hydrogen, aryl, heteroaryl, cycloalkyl, alkyl or alkyl substituted with aryl, heteroaryl, hydroxy, alkoxy, amino, monoalkyl amino or dialkylamino, or --$(CH_2)_m$ $TCOR^{20}$ wherein m is an integer from 1 to 6, T is oxygen or --NH-- and R^{20} is hydrogen, aryl, heteroaryl, alkyl or alkyl substituted with aryl or heteroaryl;
- R^3 is hydrogen, halo, trifluoromethyl, alkoxy, alkylthio, alkyl, cycloalkyl, aryl, aminosulfonyl, amino, monoalkylamino, dialkylamino, hydroxyalkylamino, aminoalkylamino, carboxy, alkoxycarbonyl or aminocarbonyl or alkyl substituted with aryl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino;
- R^a, R^b, R^c and R^d independently represent hydrogen, alkyl, cycloalkyl or aryl; or (R^a and R^b) or (R^c and R^d) or (R^b and R^c) can complete a saturated ring of 5- to 7-carbon atoms, or (R^a and R^b) taken together and (R^b and R^c) taken together, each complete a saturated ring of 5- to 7-carbon atoms, wherein each ring optionally can contain a sulfur or oxygen atom and whose carbon atoms may be optionally substituted with one or more or the following: alkenyl, alkynyl, hydroxy, carboxy, alkoxycarbonyl, alkyl or alkyl substituted with hydroxy, carboxy or alkoxycarbonyl; or such saturated ring can have two adjacent carbon atoms which are shared with an adjoining aryl ring; and
- n is zero or one.

[0028] The invention further provides the use of PDE 1 Inhibitors of Formula VIIIa or VIIIb as follows:

5.1: Formula VIIIa or VIIIb, wherein J = O

5.2: Formula VIIIa or VIIIb or 5.1, wherein R^1 is alkyl.

5.3: Formula VIIIa or VIIIb, 5.1 or 5.2, wherein R^2 is hydrogen, benzyl, 4-chlorobenzyl, cyclohexylmethyl or trimethylacetoxymethyl.

5.4: Formula VIIIa or VIIIb, 5.1, 5.2 or 5.3, wherein R^3 is hydrogen, or alkyl such as methyl or ethyl.

5.5: Formula VIIIa or VIIIb, 5.1, 5.2, 5.3 or 5.4, wherein n is zero; and

5.6: Formula VIIIa or VIIIb, 5.1, 5.2, 5.3, 5.4 or 5.5, wherein R^a and R^b form a saturated 5 membered ring, or (R^b and R^c) form a saturated 5,

6 or 7 membered ring, or (R^a and R^b) and (R^b and R^c) each complete a saturated ring and each ring contains 5 or 6 carbon atoms.

5.7 Formula VIIIa or VIIIb, in free or salt form, selected from the following:

- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(phenylmethyl)cyclopenta[4,5]imidazo-[2,1-b]purin-4-one;
- 7,8-Dihydro-5-methyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- cis-6a,7,8,9,10,10a-Hexahydro-5-methyl-3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)-one;
- 5,7,8,9-Tetrahydro-5-methyl-3-(phenylmethyl)pyrimido[2,1-b]purin-4(3H)-one;
- 7,8-Dihydro-8-phenyl-5-methyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 5', 7'-Dihydro-5'-methyl-3'-(phenylmethyl)spiro[cyclohexane-1,8'-(8H)imidazo-[2,1-b]purin]4'(3'H)-one;
- cis-5,6a,11,11a-Tetrahydro-5-methyl-3-(phenylmethyl)indeno[1',2':4,5]imidazo-[2,1-b]purin-4(3H)-one;
- 5',7'-Dihydro-2',5'dimethyl-3'-(phenylmethyl)spiro{cyclohexane-1,7'(8'H)-imidazo[2,1-b]purin}-4'-(3'H)-one;
- 7,8-Dihydro-2,5,7,7,8(R,S)-pentamethyl-3H-imidazo[2,1-b]purin-4(5H)-one;
- cis-5,6a,7,11b-Tetrahydro-5-methyl-3-(phenylmethyl)indeno[2',1',:4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2,5-dimethyl-3-(phenylmethyl)cyclopent[4,5]-imidazo[2,1-b]purin-4-(3H)-one;
- 5'-Methyl-3'-(phenylmethyl)-spiro[cyclopentane-1,7'-(8'H)-(3'H)imidazo[2,1-b]purin]-4-(5'H)-one;
- 7,8-Dihydro-2,5,7,7-tetramethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5'H)-one;
- 7,8-Dihydro-7(R)-phenyl-2,5-dimethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;

- 7,8-Dihydro-2,5-dimethyl-3,7(R)-bis(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- (±)-7,8-Dihydro-2,5-dimethyl-7-ethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 6a(S)-7,8,9,10,10a(R)-Hexhydro-2,5-dimethyl-3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)-one;
- 6a(R)-7,8,9,10,10a(S)-hexahydro-2,5-dimethyl-3-(phenylmethyl)-3H-benzimidazo-[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(R)-isopropyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5,7(R)-trimethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- cis-7,7a,8,9,10,10a-Hexahydro-2,5-dimethyl-3-(phenylmethyl)-3H-cyclopenta-[5,6]pyrimido[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(S)-(1-methylpropyl)-3-(phenylmethyl)-3H-imidazo-[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(R)-(2-methylpropyl)-3-(phenylmethyl)-3H-imidazo-[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(R,S)-(methoxycarbonyl)-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(R,S)-(1-propyl)-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(S)-(1-methylethyl)-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5,7,7,8(R,S)-pentamethyl-3H-imidazo[2,1-b]purin-4(5H)-one;
- 5,7,8,9-Tetrahydro-2,5,7,9(R,S)-pentamethyl-3-(phenylmethyl)-pyrimido[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(S),7,8,9,9a(R)-Hexahydro-2,5-dimethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;

- cis-6a,7,8,9,10,10a-Hexahydro-2,5-dimethyl-3-(phenylmethyl)-3H -benzimidazo[2,1-b]purin-4(5H)-one;
- 5',7'-Dihydro-2',5'-dimethyl-3'-(phenylmethyl)spiro[cyclohexane-1,8-(8H)-imidazo[2,1-b]purin]-4-(3'H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2,5-dimethyl-3-(phenylmethyl)cyclohept-[6,7]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2-ethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-6a,7,8,9,10,10a-Hexahydro-5-methyl-2-ethyl-3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4-(5H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2-ethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2-phenyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-6a,7,8,9,10,10a-Hexahydro-5-methyl-2-phenyl-3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)-one;
- cis-5,6a,7,8.9,9a-Hexahydro-5-methylcyclopenta[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2,5-dimethylcyclopenta[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a(R), 7,8,9,9a(S)-Hexahydro-2,5-di-methylcyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 2',5'-dimethyl-spiro{cyclopentane-1,7'-(8'H)-(3'H)-imidazo[2,1-b]purin}-4'(5'H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(R)-(1-methylethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5,7,7-tetramethyl-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-di methyl-7(S)-(1-methylethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 6a(R),7,8,9,10,10a(S)-Hexahydro-2,5-dimethyl-3H-benzimidazo[2,1-b]purin-4(5H)-one;

- 5',7'-Dihydro-2',5'-dimethylspiro{cyclohexane-1,7-(8'H)-imidazo[2,1-b]purin}-4'(3'H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(phenylmethyl)cyclopenta[4,5]-imidazo[2,1-b]purin-4(3H)-thione;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-thione;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(4-chlorophenylmethyl)cyclopenta[4,5]-imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(cyclohexylmethyl)cyclopent[4,5]-imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(2-naphthylmethyl)cyclopent[4,5]-imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(4-bromophenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R)-7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(4-methoxyphenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2,3,5-trimethylcyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2-(hydroxymethyl)-5-methyl-3-(phenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2-methylthio-5-methyl-3-(Phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-3,4,5,6a,7,8,9,9a-Octahydro-5-methyl-4-oxo-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-2-carboxylic acid;
- cis-3,4,5,6a,7,8,9,9a-Octahydro-5-methyl-4-oxo-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-2-carboxylic acid, methyl ester;
- cis-5,6a,7,8,9,9a-Hexahydro-2-bromo-5-methyl-3-(phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)one;
- cis-5,6a,7,8,9,9a-Hexahydro-2-(methylaminosulfonyl)-5-methyl-3-(phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)one;

- cis-1-Cyclopentyl-5,6a,7,8,9,9a-hexahydro-5-methylcyclopent[4,5]imidazo[2,1-b]purin-4-(1H)one;
- cis-5,6a,7,8,9,9a-Hexahydro-3,5-bis-(phenylmethyl)cyclopent(4,5)imidazo(2,1-b)purin-4(3H)one;
- cis-6a,7,8,9,10,10a-Hexahydro-3,5-bis-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)one;
- cis-3-Cyclopentyl-5,6a,7,8,9,9a-hexahydro-5-methylcyclopent[4,5]imidazo(2,1-b)purin-4(3H)one;
- 5' -Methyl-3'-(phenylmethyl)spiro[cyclopentane-1,7-(8'H)-(3'H)imidazo[2,1-b]purin]-4-(5H)one;
- 2',5'-Dimethyl-3'-(phenylmethyl)-spiro[cyclopentane-1,7-(8'H)-(3H)imidazo[2,1-b]purin]-4-(5'H)one;
- cis-5,6a,(R)7,8,9,9a(S)-Hexahydro-5-methyl-3-(phenylmethyl)cyclopent[4,5]-imidazo(2,1-b)purin-4(3H)one;
- cis-3-Cyclopentyl-5,6a,7,8,9,9a-Hexahydro-2,5-dimethylcyclopent[4,5]imidazo-[2,1-b]purin-4(3H)one;
- 5'-Methyl-2'-trifluoromethyl-3'-(phenylmethyl)spiro{cyclo-pentane-1,7'(8'H)-(3'H)imidazo[2,1-b]purin}-4-(5'H)-one;
- 7,8-Dihydro-5,7,7-trimethyl-2-trifluoromethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- (+/-)-cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2-trifluoromethyl-3-(phenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- (+/-)-6a,7,8,9,9a,10,11,11 a-Octahydro-2,5-dimethyl-3-(phenylmethyl)-3H-pentaleno[6a',1':4,5]imidazo[2,1-b]purin-4(5H)-one;
- (+)-6a,7,8,9,9a,10,11,11a-Octahydro-2,5-dimethyl-3-phenylmethyl-3H-pentaleno[6a',1':4,5]imidazo[2,1-b]purin-4(5H)-one;
- (-)-6a,7,8,9,9a,10,11,11a-Octahydro-2,5-dimethyl-3-phenylmethyl-3H-pentaleno[6a',1':4,5]Imidazo[2,1-b]purin-4(5H)-one;
- (+/-) 6a,7,8,9,9a,10,11,11a-Octahydro-2,5-dimethyl-3H-pentaleno[6a',1':4,5]-imidazo[2,1-b]purin-4(5H)-one;

- (+)-6a,7,8,9,9a,10,11,11a-Octahydro-2,5-dimethyl-3H-pentaleno[6a',1':4,5]-imidazo[2,1-b]purin-4(5H)-one;
- (-)-6a,7,8,9,9a,10,11,11a-Octahydro-2,5-dimethyl-3H-pentaleno[6a',1':4,5]-imidazo[2,1-b]purin-4(5H)-one;
- 6a,7,8,9,10,10a,11,12,13,13a-Decahydro-2,5-dimethyl-(3-phenylmethyl)-napth[1,8a-d]imidazo[2,1-b]purin-4(5H)one;
- 7(R)-Cyclohexyl-7,8-dihydro-2,5-dimethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(3H)-one;
- 7(R)-Cyclohexyl-7,8-dihydro-2,5-dimethyl-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7(S)-Cyclohexyl-7,8-dihydro-2,5-dimethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(3H)-one;
- 7(S)-Cyclohexyl-7,8-dihydro-2,5-dimethyl-3H-imidazo[2,1-b]purin-4(5H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-[3-(trimethylacetoxy)methyl]-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(4-pyridylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-[2-(4-morpholinyl)-ethyl]cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-[acetoxymethyl]cyclopent-[4,5]imidazo[2.1-b]purin-4(3H)-one;
- 5,6a,7,8,9,9a-Hexahydro-2,5,6a-trimethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5,6a-trimethyl-3-(phenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(S),7,8,9,9a(R)-Hexahydro-2,5,6a-trimethyl-3-(phenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-6a,7,8,9, 10,10a-Hexahydro-2,5,7-trimethyl-3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2,5,6a-trimethylcyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one; or

- cis-[6a,7,8,9,10,10a-Hexahydro-2,5,7-trimethyl-3H-benzimidazo[2,1-b]purin-4(5H)-one],

in free or salt form.

5.8: A compound which is a substituted imidazo[2,1-b]purin-4-one, in free or pharmaceutically acceptable salt form, e.g. a compound of Formula VIIIa, VIIIb or according to any of formulae 5.1-5.7, wherein the compound inhibits phosphodiesterase-mediated (e.g., PDE1-mediated, especially PDE1B-mediated) hydrolysis of cGMP, e.g., with an IC_{50} of less than 10 μM, preferably less than 100 nM in an immobilized-metal affinity particle reagent PDE assay, for example, as described in Example 1 below.

[0029] In another embodiment, the PDE 1 Inhibitors for use in the methods of treatment described herein are Compounds of Formula IXa or IXb



Formula IXa



Formula IXb

or a pharmaceutically acceptable salt thereof, wherein,

q=0 or 1;

R^1 is H, cycloalkyl, alkyl, R^{23}-alkyl- or R^{26};

R^a, R^b and R^c are, independently of one another, each H, alkyl, cyoloalkyl, aryl, R^{22}-aryl- or R^{24}-alkyl-; or

R^a and R^b, together with the carbon to which they are both attached, form a 4- to 7-membered ring, and R^c is H or alkyl; or

R^a and R^c, together with the respective carbons to which they are attached, form a 4- to 7-membered ring, and R^b is H or alkyl;

(i) X is a bond;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is monohaloalkyl, polyhaloalkyl, provided that it is not trifluoromethyl, azido, cyano, oximino, cycloalkenyl, heteroaryl, R^{22}-heteroaryl- or R^{27}-alkyl-;

(ii) X is a bond;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is H, halo, —CONHR^6, —CONR^{6}R^7, —CO_2R^6, monohaloalkyl, polyhaloalkyl, azido, cyano, —C=N—OR^6, cycloalkyl, cycloalkylalkyl, R^{26}, aminosulfonyl, alkyl or R^{23}-alkyl-

(iii) X is —O— or —S—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is R^{26}, cycloalkyl cycloalkylalkyl, heterocycloalkyl, cycloalkenyl or R^{26}-alkyl-;

(iv) X is —O— or —S—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is alkyl, R^{26}, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, cycloalkenyl or R^{28}-alkyl-;

(v) X is —SO— or —SO_2—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is alkyl, R^{26}, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, cycloalkenyl or R^{28}-alkyl-;

(vi) X is —NR^8—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is $(R^{29})_p$-alkyl-, cycloalkyl, $(R^{30})_p$-cycloalkyl-, cycloalkenyl, $(R^{30})_p$-cycloalkenyl-, heterocycloalkyl or $(R^{30})_p$-heterocycloalkyl-:

(vii) X is —NR^8—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is alkyl, R^{26}, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, cycloalkenyl or R^{31}-alkyl-; or

(viii) X is —C≡C—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is alkyl, R^{26}, cycloalkyl, cycloalkylalkyl or R^{23}-alkyl-;

where,

R^6 is H or R^7;

R^7 is alkyl, cycloalkyl or cycloalkylalkyl;

R^8 is heterocycloalkyl or R^6;

R^{21} is 1-6 substituents each independently selected from the group consisting of halo, hydroxy, alkoxy, phenoxy, phenyl, nitro, aminosulfonyl, cyano, monohaloalkyl, polyhaloalkyl, thiol, alkylthio, cyoloalkyl, cycloalkylalkyl, amino, alkylamino, acylamino, carboxyl, —C(O)OR^{34}, carboxamido, —OCF_3 and acyloxy;

R^{22} is 1-6 substituents each independently selected from the group consisting of alkyl and R^{21};

R^{23} is cycloalkoxy aryloxy, alkylthio, arylthio, cycloalkyl or R^{28};

R^{24} is cycloalkyl or R^{26};

R^{25} is hydroxy, alkoxy, amino, monoalkylamino, dialkylamino or R^{26};

R^{26} is aryl, R^{22}-aryl-, heteroaryl or R^{22}-heteroaryl-;

R^{27} is cycloalkoxy, aryloxy, alkylthio, arylthio, heteroaryl, R^{22}-heteroaryl-, cycloalkyl, heterocycloalkyl, cycloalkenyl, cycloalkylamino or heterocycloalkylamino;

R^{28} is cycloalkylamino, heterocycloalkylamino or R^{25};

R^{29} is alkoxy, cycloalkylamino, heterocycloalkylamino or R^{26};

R^{30} is halo, hydroxy, alkoxy, amino, aminosulfonyl, cyano, monohaloalkyl, polyhaloalkyl, thiol, alkylthio, alkyl, cyoloalkyl, cycloalkylalkyl or acyloxy;

R^{31} is cycloalkyl or R^{28};

R^{34} is alkyl, aryl, aralkyl and heteroaryl; and

p is 1 to 4.

[0030] The invention further provides the use of PDE 1 Inhibitors of Formula IXa or IXb as follows:

6.1 Formula IXa or IXb selected from a group consisting of:































































and .

6.2 Formula IXa or IXb, in free or salt form, selected from a group consisting of:


Cl
OH
O
N
N
N
N
N
H

,


O
N
N
N
N
N
OH

,

,


Cl
O
O
N
N
N
N
N
NH

,


Cl
O
O
N
N
N
N
N
NH

,


O
O
S
NH2
O
N
N
N
N
N
NH
H
H

,


O
Br
O
N
N
N
N
N
NH

,



,



,



,



,



,



,










,



,



,



,



,



,


,

,

,

, and

, in free or salt form.

[0031] In another embodiment, the invention provides the use of PDE 1 Inhibitors of Formula X:



Formula X

in free or a pharmaceutically acceptable salt thereof, wherein:

R_1, R_2 and R_3 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogeno, hydroxy, (di-lower alkyl)amino, 4-morpholinyl, 1-pyrrolidinyl, 1-pyrrolyl, --CF_3, --OCF_3, phenyl and methoxyphenyl; or R_1 and R_2 together are methylenedioxy; or R_1 and R_2 together with the carbon atoms to which they are attached form a benzene ring; and

R^a is hydrogen and R^b and R^c, together with the carbon atoms to which they are attached, form a saturated ring of 5 carbons; or R^a is lower alkyl, R^b is hydrogen or lower alkyl, and R^c is hydrogen; or R^a, R^b and the carbon atom to which they are attached form a saturated ring of 5-7 carbons, and R^c is hydrogen; or R^a is hydrogen, and R^b, R^c and the carbon atoms to which they are attached form a tetrahydrofuran ring; or R^a and R^b, together with the carbon atom to which they are attached, and R^b and R^c, together with the carbon atoms to which they are attached, each form a saturated ring of 5-7 carbons.

[0032] In a further embodiment, the invention provides the use of PDE 1 Inhibitors of Formula X as follows:

7.1 Formula X, wherein R_1, R_2 and R_3 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogeno, hydroxy, (di-lower alkyl)amino, 4-morpholinyl, 1-pyrrolidinyl, 1-pyrrolyl, --CF_3, --OCF_3, phenyl and methoxyphenyl; or R_1 and R_2 together are methylenedioxy; or R_1 and R_2 together with the carbon atoms to which they are attached form a benzene ring;

7.2 Formula X or 7.1, wherein R_1 is H, methoxy or trifluoromethyl;

7.3 Formula X or 7.1 or 7.2, wherein R_1 is H;

7.4 Formula X or any of 7.1-7.3, wherein R_2 is selected from a group consisting of H, halo (e.g., F, Cl), methoxy, methyl, trifluoromethyl, dimethylamino, phenyl, methoxyphenyl-, -OCF_3, 3,4-OCH_2O-, pyrolidin-1-yl, pyrol-1-yl and morpholin-4-yl;

7.5 Formula X or any of 7.1-7.4, wherein R_1 and R_2 together with the carbon atoms to which they are attached forma a benzene ring;

7.6 Formula X or any of 7.1-7.5, wherein R_3 is H or methoxy;

7.7 Formula X or any of 7.1-7.6, wherein R_3 is H;

7.8 Formula X or any of 7.1-7.7, wherein R^a is hydrogen and R^b and R^c, together with the carbon atoms to which they are attached, form a saturated ring of 5 carbons; or R^a is lower alkyl, R^b is hydrogen or lower alkyl, and R^c is hydrogen; or R^a, R^b and the carbon atom to which they are attached form a saturated ring of 5-7 carbons, and R^c is hydrogen; or R^a is hydrogen, and R^b, R^c and the carbon atoms to which they are attached form a tetrahydrofuran ring; or R^a and R^b, together with the carbon atom to which they are attached, and R^b and R^c, together with the carbon atoms to which they are attached, each form a saturated ring of 5-7 carbons;

7.9 Formula X or any of 7.1-7.8, wherein R^a is hydrogen and R^b and R^c together with the carbon atoms to which they are attached, form a saturated ring of 5 carbons, and wherein R_1, R_2 and R_3 are as defined in the following table

R_1	R_2	R_3
H	H	H
$-OCH_3$	H	H
H	F	H
H	$-OCH_3$	H
H	OH	H
H	$-CH_3$	H
H	$(CH_3)_2N-$	H
$-OCH_3$	$-OCH_3$	$-OCH_3$
$-OCH_3$	$-OCH_3$	H
$-CF_3$	H	H
H	C_6H_5-	H

H	—OCF_3	H
H		H
H		H
	3,4-OCH_2O—	H
H		H
H		H
R_1 and R_2, together with the carbon atoms to which they are attached form a benzene ring		H
H	Cl	H.

7.10 Formula X or any of 7.1-7.9, selected from a group consisting of



,



,


,


,


,


,


and



7.11 Formula X or any of 7.1-7.9, selected from a group consisting of:

2'-benzyl-5'-methyl-spiro[cyclopentane-1',7' (8'H)-[3'H]-imidazo[2,1-b]purin]-4'-(5'H)-one;

2'-benzyl-5,7,7-trimethyl-3H-imidazo[2,1-b]purin-4-(5H)-one;

(+)-2-benzyl-7,8-dihydro-5-methyl-7-(1-methylethyl)-1H-imidazo[2,1-b]-purin-4(5H)-one;

(+,-)-6a, 7, 8, 9, 9a, 10, 11, 11a-octahydro-5-methyl-2-(3,4-methylene-dioxyphenylmethyl)-3H-pentalen[6a, 1:4,5]imidazo[2,1-b]purin-4(5H)-one; and

(+)-cis-6a, 7, 9, 9a-tetrahydro-5-methyl-2-[4-(trifluoromethyl)-phenylmethyl]-3H-furo[3', 4':4,5]imidazo[2,1-b]purin-4(5H)-one,

in free or salt form.

7.12 Formulae X or 7.1-7.11, wherein the compounds inhibit phosphodiesterase-mediated (e.g., PDE1-mediated, especially PDE1B-mediated) hydrolysis of cGMP, e.g., with an IC_{50} of less than 1μM, preferably less than 25 nM in an immobilized-metal affinity particle reagent PDE assay, for example, as described in Example 1;

[0033] In another embodiment, the invention provides the use of PDE 1 Inhibitors selected from the following:


,

,

and


in free or salt form (Formula XI).

[0034] If not otherwise specified or clear from context, the following terms as used herein have the following meanings:

a. "Alkyl" as used herein is a saturated or unsaturated hydrocarbon moiety, preferably saturated, preferably one to seven carbon atoms in length, which may be linear or branched, and may be optionally substituted, e.g., mono-, di-, or tri-substituted, e.g., with halogen (e.g., chloro or fluoro), hydroxy, or carboxy.

b. "Cycloalkyl" as used herein is a saturated or unsaturated nonaromatic hydrocarbon moiety, preferably saturated, preferably comprising three to nine carbon atoms, at least some of which form a nonaromatic mono- or bicyclic, or bridged cyclic structure, and which may be optionally substituted, e.g., with halogen (e.g., chloro or fluoro), hydroxy, or carboxy.

c. "Heterocycloalkyl" as used herein is a saturated or unsaturated nonaromatic hydrocarbon moiety, preferably saturated, preferably comprising three to nine carbon atoms, at least one atom selected

from a group consisting of N, O or S, at least some of which form a nonaromatic mono- or bicyclic, or bridged cyclic structure, and which may be optionally substituted, e.g., with halogen (e.g., chloro or fluoro), hydroxy, or carboxy. Examples of heterocycloalkyl include pyrrolidinyl (e.g., pyrrolidin-1-yl), morpholinyl (e.g., morpholin-4-yl),

d. "Aryl" as used herein is a mono or bicyclic aromatic hydrocarbon (e.g., phenyl, naphthyl), preferably phenyl, optionally substituted, e.g., with alkyl (e.g., methyl), halogen (e.g., chloro or fluoro), haloalkyl (e.g., trifluoromethyl), hydroxy, carboxy, or an additional aryl or heteroaryl (e.g., biphenyl or pyridylphenyl).

e. "Heteroaryl" as used herein is an aromatic moiety wherein one or more of the atoms making up the aromatic ring is sulfur or nitrogen rather than carbon, e.g., pyridyl, thiadiazolyl, pyrrolyl (e.g., pyrrol-2-yl) or imidazolyl (e.g., 1H-imidazol-2-yl), which may be optionally substituted, e.g., with alkyl, halogen, haloalkyl, hydroxy or carboxy.

[0035] PDE 1 Inhibitors may exist in free or salt form, e.g., as acid addition salts. In this specification unless otherwise indicated language such as PDE 1 Inhibitors is to be understood as embracing the compounds in any form, for example free or acid addition salt form, or where the compounds contain acidic substituents, in base addition salt form. The PDE 1 Inhibitors are intended for use as pharmaceuticals, therefore pharmaceutically acceptable salts are preferred. Salts which are unsuitable for pharmaceutical uses may be useful, for example, for the isolation or purification of free PDE 1 Inhibitors or their pharmaceutically acceptable salts.

[0036] PDE 1 Inhibitors may in some cases also exist in prodrug form, for example when the compounds contain physiologically hydrolysable and acceptable esters. As used herein, "physiologically hydrolysable and acceptable ester" means esters of PDE 1 Inhibitors which are hydrolysable under physiological conditions to yield acids (in the case of PDE 1 Inhibitors which have hydroxy substituents) or alcohols (in the case of PDE 1 Inhibitors which have carboxy substituents) which are themselves

physiologically tolerable at doses to be administered. As will be appreciated the term thus embraces conventional pharmaceutical prodrug forms.

[0037] Methods of making and formulating the PDE 1 Inhibitors, novel intermediates useful for making PDE 1 Inhibitors, and methods of using the PDE 1 Inhibitors for treatment of diseases are generally disclosed in EP 0201188 (or U.S. 4,666,908) and EP 0911333 (or U.S. 6,235,742); PCT/US2006/022066; PCT/US2006/033179; WO 03/042216 (U.S. 6,943,171); U.S. 6,969,719; U.S. 5,939,419; EP 0 538 332 (U.S. 5,393,755); U.S. 5,393,755; U.S. 6,969,719 B2, Xia et al., *J. Med. Chem.* (1997), 40, 4372-4377 and Ahn et al., *J. Med. Chem.* (1997), 40, 2196-2210, the contents of all of which are incorporated herein by reference.

Methods of treatment

[0038] The invention provides methods of treatment or prophylaxis of narcolepsy comprising administering an effective amount of a PDE 1 inhibitor, e.g., a PDE 1 Inhibitor as hereinbefore described, for example a Compound of any of Formulae I, Ia, II, III, IV, V, VI, VIIa, VIIb, VIIIa, VIIIb, IXa, IXb, X, XI or any of Formulae 1.2-1.17, 2.1-2.9, or 3.2-3.22, 4.1-4.17, 5.1-5.8, 6.1-6.1 or 7.1-7.12 to a human or animal patient, preferably a human, in need thereof.

[0039] PDE 1 Inhibitors may be used in the foregoing methods of treatment prophylaxis as a sole therapeutic agent, but may also be used in combination or for co-administration with other active agents. Thus, the invention further comprises a method of treating narcolepsy comprising administering simultaneously, sequentially, or contemporaneously administering therapeutically effective amounts of

(i) a PDE 1 Inhibitor, e.g., any of Formulae I, Ia, II, III, IV, V, VI, VIIa, VIIb, VIIIa, VIIIb, IXa, IXb, X, XI or any of Formulae 1.2–1.17, 2.1-2.9, 3.2-3.22, 4.1-4.17, 5.1-5.8, 6.1-6.2 or 7.1-7.12; and

(ii) a compound to promote wakefulness or regulate sleep, e.g., selected from (a) central nervous system stimulants-amphetamines and amphetamine like compounds, e.g., methylphenidate, dextroamphetamine, methamphetamine, and pemoline; (b) modafinil, (c) antidepressants, e.g., tricyclics (including

imipramine, desipramine, clomipramine, and protriptyline) and selective serotonin reuptake inhibitors (including fluoxetine and sertraline); and/or (d) gamma hydroxybutyrate (GHB),

to a patient in need thereof.

[0040] The present invention also provides

(i) a PDE 1 Inhibitor for use in the treatment of any disease or condition as hereinbefore set forth, or in a method of treatment as hereinbefore set forth;

(ii) the use of a PDE 1 Inhibitor in the manufacture of a medicament for treating a disease or condition as hereinbefore set forth, or manufacture of a medicament for use in a method of treatment as hereinbefore set forth; and

(iii) a pharmaceutical composition comprising a PDE 1 Inhibitor in combination or association with a pharmaceutically acceptable diluent or carrier for use in the treatment of a disease or condition as hereinbefore set forth, or for use in a method of treatment as hereinbefore set forth.

[0041] The words "treatment" and "treating" are to be understood accordingly as embracing prophylaxis and treatment or amelioration of any of the symptoms of disease as well as treatment of the cause of the disease.

[0042] Dosages employed in practicing the present invention will of course vary depending, e.g. on the particular disease or condition to be treated, the particular PDE 1 Inhibitor used, the mode of administration, and the therapy desired. PDE 1 Inhibitors may be administered by any suitable route, including orally, parenterally, transdermally, or by inhalation, but are preferably administered orally. In general, satisfactory results, e.g. for the treatment of diseases as hereinbefore set forth are indicated to be obtained on oral administration at dosages of the order from about 0.01 to 2.0 mg/kg. In larger mammals, for example humans, an indicated daily dosage for oral administration will accordingly be in the range of from about 0.75 to 150 mg, conveniently administered once, or in divided doses 2 to 4 times, daily or in sustained release form. Unit dosage forms for oral administration thus for example may comprise from about 0.2 to 75 or 150 mg, e.g. from about 0.2 or 2.0 to 50, 75 or 100 mg of a PDE 1 Inhibitor, together with a pharmaceutically acceptable diluent or carrier therefor.

[0043] Pharmaceutical compositions comprising PDE 1 Inhibitors may be prepared using conventional diluents or excipients and techniques known in the galenic art. Thus oral dosage forms may include tablets, capsules, solutions, suspensions and the like.

EXAMPLES

1. Measurement of PDE1B inhibition *in vitro* using IMAP Phosphodiesterase Assay Kit

[0044] Phosphodiesterase 1B (PDE1B) is a calcium/calmodulin dependent phosphodiesterase enzyme that converts cyclic guanosine monophosphate (cGMP) to 5'-guanosine monophosphate (5'-GMP). PDE1B can also convert a modified cGMP substrate, such as the fluorescent molecule cGMP-fluorescein, to the corresponding GMP-fluorescein. The generation of GMP-fluorescein from cGMP-fluorescein can be quantitated, using, for example, the IMAP (Molecular Devices, Sunnyvale, CA) immobilized-metal affinity particle reagent.

[0045] Briefly, the IMAP reagent binds with high affinity to the free 5'-phosphate that is found in GMP-fluorescein and not in cGMP-fluorescein. The resulting GMP-fluorescein – IMAP complex is large relative to cGMP-fluorescein. Small fluorophores that are bound up in a large, slowly tumbling, complex can be distinguished from unbound fluorophores, because the photons emitted as they fluoresce retain the same polarity as the photons used to excite the fluorescence.

[0046] In the phosphodiesterase assay, cGMP-fluorescein, which cannot be bound to IMAP, and therefore retains little fluorescence polarization, is converted to GMP-fluorescein, which, when bound to IMAP, yields a large increase in fluorescence polarization (Δmp). Inhibition of phosphodiesterase, therefore, is detected as a decrease in Δmp.

Enzyme assay

[0047] Materials: All chemicals are available from Sigma-Aldrich (St. Louis, MO) except for IMAP reagents (reaction buffer, binding buffer, FL-GMP and IMAP beads), which are available from Molecular Devices (Sunnyvale, CA).

[0048] Assay: 3',5'-cyclic-nucleotide-specific bovine brain phosphodiesterase (Sigma, St. Louis, MO) is reconstituted with 50% glycerol to 2.5 U/ml. One unit of enzyme will hydrolyze 1.0 μmole of 3',5'-cAMP to 5'-AMP per min at pH 7.5 at 30°C. One part enzyme is added to 1999 parts reaction buffer (30 μM $CaCl_2$, 10 U/ml of calmodulin (Sigma P2277), 10mM Tris-HCl pH 7.2, 10mM $MgCl_2$, 0.1% BSA, 0.05% NaN_3) to yield a final concentration of 1.25mU/ml. 99 μl of diluted enzyme solution is added into each well in a flat bottom 96-well polystyrene plate to which 1 μl of test compound dissolved in 100% DMSO is added. The compounds are mixed and pre-incubated with the enzyme for 10 min at room temperature.

[0049] The FL-GMP conversion reaction is initiated by combining 4 parts enzyme and inhibitor mix with 1 part substrate solution (0.225 μM) in a 384-well microtiter plate. The reaction is incubated in dark at room temperature for 15 min. The reaction is halted by addition of 60 μl of binding reagent (1:400 dilution of IMAP beads in binding buffer supplemented with 1:1800 dilution of antifoam) to each well of the 384-well plate. The plate is incubated at room temperature for 1 hour to allow IMAP binding to proceed to completion, and then placed in an Envision multimode microplate reader (PerkinElmer, Shelton, CT) to measure the fluorescence polarization (Δmp).

[0050] A decrease in GMP concentration, measured as decreased Δmp, is indicative of inhibition of PDE activity. IC_{50} values are determined by measuring enzyme activity in the presence of 8 to 16 concentrations of compound ranging from 0.0037 nM to 80,000 nM and then plotting drug concentration versus ΔmP, which allows IC_{50} values to be estimated using nonlinear regression software (XLFit; IDBS, Cambridge, MA).

What is claimed is:

1. A method of treatment or prophylaxis for narcolepsy comprising administering an effective amount of a PDE 1 inhibitor to a patient in need thereof.

2. The method of claim 1 wherein the PDE 1 inhibitor is a compound of the formula (I)



Formula I

wherein

(i) R_1 is H or C_{1-4} alkyl;

(ii) R_4 is H or C_{1-4} alkyl and R_2 and R_3 are, independently, H or C_{1-4} alkyl, aryl, heteroaryl, heteroarylalkoxy, arylalkoxy, heteroarylaklyl, or arylalkyl;
or R_2 is H and R_3 and R_4 together form a di-, tri-, or tetra-methylene bridge;

(iii) R_5 is a substituted heteroarylalkyl, or R_5 is attached to one of the nitrogen atoms on the pyrazolo portion of Formula I and is a moiety of Formula Q



Formula Q

wherein X, Y and Z are, independently, N or C; R_8, R_9, R_{11} and R_{12} are independently H or halogen; and R_{10} is halogen, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or thiadiazolyl, diazolyl, triazolyl, tetrazolyl, arylcarbonyl, alkylsulfonyl, heteroarylcarbonyl, or alkoxycarbonyl; provided that when X, Y, or Z is nitrogen, R_8, R_9, or R_{10}, respectively, is not present;

(iv) R_6 is H, alkyl, aryl, heteroaryl, arylalkyl, arylamino, heterarylamino, N,N-dialkylamino, N,N-diarylamino, or N-aryl-N-(arylakyl)amino; and

(v) n=0 or 1;

(vi) when n=1, A is $-C(R_{13}R_{14})-$

wherein R_{13} and R_{14}, are, independently, H or C_{1-4} alkyl, aryl, heteroaryl, heteroarylalkoxy, arylalkoxy, heteroarylalkyl or arylalkyl;

in free, salt or prodrug form.

3. The method according to claim 1, wherein the PDE 1 inhibitor is a compound of Formula II



Formula II

wherein

R_a and R_b are, independently, H or C_{1-4} alkyl;

R_6 is phenylamino or benzylamino;

R_{10} is phenyl, pyridyl, or thiadiazolyl;

in free or salt form.

4. The method according to claim 1 wherein the PDE 1 inhibitor is a compound of Formula III



Formula III

wherein

R_2 is H and R_3 and R_4 together form a tri- or tetra-methylene bridge; or at least one of R_2 and R_3 is methyl, isopropyl or arylalkoxy and R_4 is H; or R_2 and R_3 are H and R_4 is a C_{1-4} alkyl;

R_6 is phenylamino or benzylamino;

R_{10} is haloalkyl, phenyl, pyridyl, or thiadiazolyl;

in free or salt form.

5. The method according to claim 1 wherein the PDE 1 inhibitor is a compound of Formula IV



Formula IV

wherein

R_2 is H and R_3 and R_4 together form a tri- or tetra-methylene bridge; or at least one of R_2 and R_3 is methyl, isopropyl or arylalkoxy and R_4 is H; or R_2 and R_3 are H and R_4 is a C_{1-4} alkyl;

R_6 is phenylamino or benzylamino;

R_{10} is phenyl, pyridyl, or thiadiazolyl;

in free or salt form.

6. The method according to claim 1 wherein the PDE 1 inhibitor is a compound of formula Ia



Formula Ia

wherein

(i) R_1 is H or C_{1-4} alkyl;

(ii) R_4 is H and R_2 and R_3 are, independently, H or C_{1-4} alkyl, aryl, or arylalkyl; or R_2 is H and R_3 and R_4 together form a di-, tri- or tetramethylene bridge;

(iii) R_5 is attached to one of the nitrogens on the pyrazolo portion of formula I and is a substituted benzyl of formula Qa



Formula Qa

wherein R_8, R_9, R_{11} and R_{12} are independently H or halogen; and R_{10} is halogen, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, arylcarbonyl, alkyl sulfonyl or heteroarylcarbonyl, and

(iv) R_6 is H, alkyl, aryl, heteroaryl, arylalkyl, arylamino, heteroarylamino, arylalkylamino, N,N-dialkylamino, N,N-diarylamino, or N-aryl-N-(arylalkyl)amino;

in free, salt or prodrug form.

7. The method according to claim 1 wherein the PDE 1 inhibitor is a compound of Formula V



Formula V

wherein

R_2 is H and R_3 and R_4 together form a tri- or tetra-methylene bridge; or R_2 and R_3 are each methyl and R_4 is H; or R_2 and R_4 are H and R_3 is isopropyl;

R_6 is phenylamino or benzylamino;

R_{10} is phenyl, pyridyl, or thiadiazolyl;

in free or salt form.

8. The method of claim 1 wherein the PDE 1 inhibitor is a compound of the Formula (VI)



Formula VI

wherein

R_a is methyl or C_2-C_6 alkyl;

R_1 is H or C_1-C_4 alkyl;

each of R_2 and R_3 is independently selected from H and C_1-C_4 alkyl, or R_2 is H or C_1-C_4 alkyl and R_3 is OH, C_2-C_4 alkanoyloxy or fluoro, or R_2 and R_3 when taken together represent C_2-C_6 alkylene, or R_2 and R_3 when taken together with the carbon atom to which they are attached represent a carbonyl group;

Ar is either (a)



wherein

each of R_4, R_5 and R_6 is independently selected from

H
C_1-C_4 alkyl,
C_1-C_4 alkoxy,
C_1-C_4 alkoxy-Z-,
halo,
halo(C_1-C_4)alkyl,
phenoxy, optionally substituted by up to three substitutents each of which substitutent is independently selected from halo, C_{1-4} alkyl, and C_1-C_4 alkoxy,
nitro,
hydroxy,
hydroxy-Z-,
C_2-C_4 alkanoyl,
amino,
amino-Z-,
(C_1-C_4 alkyl)NH,
(C_1-C_4 alkyl)$_2$N-,
(C_1-C_4 alkyl)NH-Z-,
(C_1-C_4 alkyl)$_2$N-Z-,
-COOH,
-Z-COOH,
-COO(C_1-C_4 alkyl),
-Z-COO(C_1-C_4 alkyl)
C_1-C_4 alkanesulphonamido,
C_1-C_4 alkanesulphonamido-Z-,
halo(C_1-C_4)alkanesulphonamido,

halo(C_1-C_4)alkanesulphonamido-Z-,

C_1-C_4 alkanamido,

C_1-C_4 alkanamido-Z-,

HOOC-Z-NH-,

HOOC-Z-NH-Z-,

(C_1-C_4 alkyl)OOC-Z-NH-,

(C_1-C_4 alkyl)OOC-Z-NH-Z-,

C_1-C_4 alkyl-NH-SO_2-NH-,

C_1-C_4 alkyl-NH-SO_2-NH-Z-,

(C_1-C_4 alkyl)$_2$-N-SO_2-NH-,

(C_1-C_4 alkyl)$_2$-N-SO_2-NH-Z-,

C_1-C_4 alkoxy CH=CH-Z-CONH-,

C_1-C_4 alkoxy CH=CHCONH

C_1-C_4 alkyl-SO_2-N(C_1-C_4 alkyl)-,

C_1-C_4 alkyl-SO_2-N(C_1-C_4 alkyl)-Z-,

(C_1-C_4 alkyl)NH-Z-SO_2-NH-,

(C_1-C_4 alkyl)$_2$N-Z-SO_2-NH-,

(C_1-C_4 alkyl)NH-Z-SO_2-NH-Z-,

(C_1-C_4 alkyl)$_2$N-Z-SO_2-NH-Z-,

benzenesulphonamido, optionally ring substituted by up to three substitutents each of which is independently selected from halo, C_{1-4} alkyl, and C_1-C_4 alkoxy,

C_1-C_4 alkanoyl-N(C_1-C_4 alkyl)-,

C_1-C_4 alkanoyl-N(C_1-C_4 alkyl)-Z-,

C_1-C_4 alkoxycarbonyl-CH(CH_2OH)$NHSO_2$-,

-SO_3H,

-SO_2NH_2,

H_2NOC-CH(CH_2OH)-$NHSO_2$-,

HOOC-Z-O-, and

(C_1-C_4 alkyl)OOC-Z-O-,

or optionally one of R_4, R_5 and R_6 is a G-Het group and wherein the others of R_4, R_5 and R_6 are independently selected from the R_4, R_5 and R_6 substitutents listed above;

Z is C_1-C_4 alkylene,

G is a direct link, Z, O, -SO_2NH-, SO_2, or -Z-N(C_1-C_4 alkyl)SO_2-,

Het is a 5- or 6-membered heterocyclic group containing 1, 2, 3 or 4 nitrogen heteroatoms; or 1 or 2 nitrogen heteroatoms and 1 sulphur heteroatom or 1 oxygen heteroatom; or the heterocyclic group is furanyl or thiophenyl; wherein the Het group is saturated or partially or fully unsaturated and optionally substituted by up to 3 substitutents, wherein each substitutent is independently selected from C_1-C_4 alkyl, oxo, hydroxy, halo, and halo(C_1-C_4) alkyl;

or (b) any one of the following bicyclic groups:

benzodioxolanyl,
benzodioxanyl,
benzimidazolyl,
quinolinyl,
indolyl,
quinazolinyl,
isoquinolinyl,
benzotriazolyl,
benzofuranyl,
benzothiophenyl,
quinoxalinyl, or
phthalizinyl,

wherein said bicyclic Ar groups are linked to the neighbouring -C(R_2R_3)- group *via* the benzo ring portion,

and wherein the heterocyclic portion of said bicyclic Ar group is optionally partially or fully saturated, said group being optionally substituted by one or more of C_1-C_4 alkyl, halo, hydroxy, oxo, amino, and C_1-C_4 alkoxy;

in free or pharmaceutically acceptable salt form.

9. The method according to claim 1 wherein the PDE 1 inhibitor is selected from the following:







in free or pharmaceutically acceptable salt form.

10. The method according to claim 1 wherein the compound is



in free or pharmaceutically acceptable salt form.

11. The method according to claim 1 wherein the PDE 1 inhibitor is a compound of the Formula VIIa or VIIb:



Formula VIIa



Formula VIIb

in free or salt form, wherein:

i) q = 0, 1 or 2;

ii) R^1, R^a, R^b, R^c and R^d are each independently H, alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups,

wherein each alkyl group of R^1, R^a, R^b, R^c and R^d is independently unsubstituted or substituted with 1 to 5 independently selected R^3 moieties which can be the same or different, each R^3 moiety being independently selected from the group consisting of hydroxy, alkoxy, cycloalkoxy, aryloxy, alkylthio, arylthio, aryl, haloaryl, heteroaryl, cycloalkyl, heterocycloalkyl, amino, alkylamino, dialkylamino, cycloalkylamino and heterocycloalkylamino groups;

wherein each of the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups of R^1, R^a, R^b, R^c and R^d is independently unsubstituted or substituted with 1 to 5 independently selected R^4 moieties which can be the same or different, each

R^4 moiety being independently selected from the group consisting of: halo, optionally substituted aryl, heteroaryl, nitro, cyano, haloalkyl, haloalkoxy, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, amino, alkylamino, dialkylamino, $-OCF_3$, acyloxy, $-OR^8$, $-C(O)R^9$, $-C(O)OR^8$, $-NR^{10}C(O)R^9$, $-NR^{10}C(O)OR^8$,- $NR^{10}S(O)_2R^9$, - $S(O)_{0-2}R^9$ groups, carbonyl when two hydrogens attached to the same carbon atom of the cycloalkyl or heterocycloalkyl group of R' are substituted, and $=CR^8R^9$ when two hydrogens attached to the same carbon atom of the cycloalkyl or heterocycloalkyl groups of R^1 are substituted,

wherein each of the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups of the $R^3$and R^4 moieties above is independently unsubstituted or substituted with 1 to 5 independently selected R^{12} moieties which can be the same or different, each R^{12} moiety being independently selected from the group consisting of: halo, phenyl, nitro, cyano, haloalkyl, haloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, amino, alkylamino, $-OCF_3$, acyloxy, $-OR^8$, $-C(O)R^9$, $-C(O)OR^8$, $-NR^{10}C(O)R^9$, $-NR^{10}C(O)OR^8$,- $NR^{10}S(O)_2R^9$, - $S(O)_{0-2}R^9$ groups, carbonyl when two hydrogens attached to the same carbon atom of the cycloalkyl or heterocycloalkyl group of R^3 or R^4 are substituted, and $=CR^8R^9$ when two hydrogens attached to the same carbon atom of the cycloalkyl or heterocycloalkyl group of R^3 or R^4 are substituted; or

iii) R^a and R^b, together with the carbon to which they are both attached, form a 4- to 7-membered cycloalkyl or heterocycloalkyl ring, and R^c and R^d are each independently H or an alkyl group; or

iv) R^a and R^c, together with the respective carbons to which they are attached, form a 4- to 7-membered cycloalkyl or heterocycloalkyl ring, and R^b and R^d are each independently H or an alkyl group, preferably R^a and R^c together have the *cis* configuration, e.g., where the carbons carrying R^a and R^c have the R and S configurations, respectively;

v) R^2 is H, halo, alkyl, haloalkyl, alkoxy, alkylthio, amino, aminosulfonyl, monoalkylamino, dialkylamino, hydroxyalkylamino, aminoalkylamino, carboxy, alkoxycarbonyl, aminocarbonyl or alkylaminocarbonyl group,

wherein each alkyl group of R^2 is independently unsubstituted or substituted with 1 to 5 independently selected R^{13} moieties which can be the same or different, each R^{13} moiety being independently selected from the group consisting of halo, hydroxy, alkoxy, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amino, monoalkylamino or dialkylamino group,

wherein each aryl group of R^{13} is independently unsubstituted or substituted with 1 to 5 independently selected R^4 moieties which can be the same or different;

vi) Y is H or an alkyl group substituted with (i) an aryl, heteroaryl, cycloalkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino group, or (ii) an aryl group substituted with from one to three moieties each independently selected from the group consisting of: halo, alkyl, phenyl, hydroxy, alkoxy, phenoxy, amino, monoalkylamino and dialkylamino group;

vii) each R^8 is independently H, alkyl or aryl;

viii) each R^9 is independently H, alkyl, aryl or $-NR^{10}R^{11}$;

ix) each R^{10} is independently H, alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, wherein each alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of R^{10} is unsubstituted or independently substituted with 1 to 5 R^{14} moieties which can be the same or different, each R^{14} moiety being independently selected from the group consisting of: halo, alkyl, aryl,

cycloalkyl, $-CF_3$, $-OCF_3$, -CN, $-OR^8$, $-CH_2OR^8$, $-C(O)OR^8$ and $-C(O)NR^8R^8$; and

x) each R^{11} is independently H, alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, wherein each alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of R^{11} is unsubstituted or independently substituted with 1 to 5 R^{14} moieties which can be the same or different.

12. The method according to claim 1, wherein the PDE 1 inhibitor is selected from the following:









in free or salt form.

13. The method according to claim 1, wherein the PDE 1 inhibitor is



in free or salt form.

14. The method according to claim 1, wherein the PDE 1 inhibitor is Compounds of Formula VIIIa or VIIIb:



Formula VIIIa



Formula VIIIb

in free or salt form, wherein:

- J is oxygen or sulfur,
- R^1 is hydrogen, alkyl or alkyl substituted with aryl or hydroxy;
- R^2 is hydrogen, aryl, heteroaryl, cycloalkyl, alkyl or alkyl substituted with aryl, heteroaryl, hydroxy, alkoxy, amino, monoalkyl amino or dialkylamino, or --$(CH_2)_m$ $TCOR^{20}$ wherein m is an integer from 1 to 6, T is oxygen or --NH-- and R^{20} is hydrogen, aryl, heteroaryl, alkyl or alkyl substituted with aryl or heteroaryl;
- R^3 is hydrogen, halo, trifluoromethyl, alkoxy, alkylthio, alkyl, cycloalkyl, aryl, aminosulfonyl, amino, monoalkylamino, dialkylamino, hydroxyalkylamino, aminoalkylamino, carboxy, alkoxycarbonyl or aminocarbonyl or alkyl substituted with aryl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino;
- R^a, R^b, R^c and R^d independently represent hydrogen, alkyl, cycloalkyl or aryl; or (R^a and R^b) or (R^c and $R^{d)}$ or (R^b and R^c) can complete a saturated ring of 5- to 7-carbon atoms, or (R^a and R^b) taken together and (R^b and R^c) taken together, each complete a saturated ring of 5- to 7-carbon atoms, wherein each ring optionally can contain a sulfur or oxygen atom and whose carbon atoms may be optionally substituted with one or more or the following: alkenyl, alkynyl, hydroxy, carboxy, alkoxycarbonyl, alkyl or alkyl substituted with hydroxy, carboxy or alkoxycarbonyl; or such saturated ring can have two adjacent carbon atoms which are shared with an adjoining aryl ring; and
- n is zero or one.

15. The method according to claim 14, wherein the PDE 1 inhibitor is Compounds of Formula VIIIa or VIIIb selected from a group consisting of:

- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(phenylmethyl)cyclopenta[4,5]imidazo-[2,1-b]purin-4-one;
- 7,8-Dihydro-5-methyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- cis-6a,7,8,9,10,10a-Hexahydro-5-methyl-3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)-one;
- 5,7,8,9-Tetrahydro-5-methyl-3-(phenylmethyl)pyrimido[2,1-b]purin-4(3H)-one;
- 7,8-Dihydro-8-phenyl-5-methyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 5', 7'-Dihydro-5'-methyl-3'-(phenylmethyl)spiro[cyclohexane-1,8'-(8H)imidazo-[2,1-b]purin]4'(3'H)-one;
- cis-5,6a,11,11a-Tetrahydro-5-methyl-3-(phenylmethyl)indeno[1',2':4,5]imidazo-[2,1-b]purin-4(3H)-one;
- 5',7'-Dihydro-2',5'dimethyl-3'-(phenylmethyl)spiro{cyclohexane-1,7'(8'H)-imidazo[2,1-b]purin}-4'-(3'H)-one;
- 7,8-Dihydro-2,5,7,7,8(R,S)-pentamethyl-3H-imidazo[2,1-b]purin-4(5H)-one;
- cis-5,6a,7,11b-Tetrahydro-5-methyl-3-(phenylmethyl)indeno[2',1',:4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2,5-dimethyl-3-(phenylmethyl)cyclopent[4,5]-imidazo[2,1-b]purin-4-(3H)-one;
- 5'-Methyl-3'-(phenylmethyl)-spiro[cyclopentane-1,7'-(8'H)-(3'H)imidazo[2,1-b]purin]-4-(5'H)-one;
- 7,8-Dihydro-2,5,7,7-tetramethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5'H)-one;
- 7,8-Dihydro-7(R)-phenyl-2,5-dimethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-3,7(R)-bis(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;

- (±)-7,8-Dihydro-2,5-dimethyl-7-ethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 6a(S)-7,8,9,10,10a(R)-Hexhydro-2,5-dimethyl-3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)-one;
- 6a(R)-7,8,9,10,10a(S)-hexahydro-2,5-dimethyl-3-(phenylmethyl)-3H-benzimidazo-[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(R)-isopropyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5,7(R)-trimethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- cis-7,7a,8,9,10,10a-Hexahydro-2,5-dimethyl-3-(phenylmethyl)-3H-cyclopenta-[5,6]pyrimido[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(S)-(1-methylpropyl)-3-(phenylmethyl)-3H-imidazo-[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(R)-(2-methylpropyl)-3-(phenylmethyl)-3H-imidazo-[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(R,S)-(methoxycarbonyl)-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(R,S)-(1-propyl)-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(S)-(1-methylethyl)-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5,7,7,8(R,S)-pentamethyl-3H-imidazo[2,1-b]purin-4(5H)-one;
- 5,7,8,9-Tetrahydro-2,5,7,9(R,S)-pentamethyl-3-(phenylmethyl)-pyrimido[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(S),7,8,9,9a(R)-Hexahydro-2,5-dimethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;

- cis-6a,7,8,9,10,10a-Hexahydro-2,5-dimethyl-3-(phenylmethyl)-3H - benzimidazo[2,1-b]purin-4(5H)-one;
- 5',7'-Dihydro-2',5'-dimethyl-3'-(phenylmethyl)spiro[cyclohexane-1,8-(8H)-imidazo[2,1-b]purin]-4-(3'H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2,5-dimethyl-3-(phenylmethyl)cyclohept-[6,7]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2-ethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-6a,7,8,9,10,10a-Hexahydro-5-methyl-2-ethyl-3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4-(5H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2-ethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2-phenyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-6a,7,8,9,10,10a-Hexahydro-5-methyl-2-phenyl-3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)-one;
- cis-5,6a,7,8.9,9a-Hexahydro-5-methylcyclopenta[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2,5-dimethylcyclopenta[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a(R), 7,8,9,9a(S)-Hexahydro-2,5-di-methylcyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 2',5'-dimethyl-spiro{cyclopentane-1,7'-(8'H)-(3'H)-imidazo[2,1-b]purin}-4'(5'H)-one;
- 7,8-Dihydro-2,5-dimethyl-7(R)-(1-methylethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5,7,7-tetramethyl-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7,8-Dihydro-2,5-di methyl-7(S)-(1-methylethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;

- 6a(R),7,8,9,10,10a(S)-Hexahydro-2,5-dimethyl-3H-benzimidazo[2,1-b]purin-4(5H)-one;
- 5',7'-Dihydro-2',5'-dimethylspiro{cyclohexane-1,7-(8'H)-imidazo[2,1-b]purin}-4'(3'H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(phenylmethyl)cyclopenta[4,5]-imidazo[2,1-b]purin-4(3H)-thione;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-thione;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(4-chlorophenylmethyl)cyclopenta[4,5]-imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(cyclohexylmethyl)cyclopent[4,5]-imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(2-naphthylmethyl)cyclopent[4,5]-imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(4-bromophenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R)-7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(4-methoxyphenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2,3,5-trimethylcyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2-(hydroxymethyl)-5-methyl-3-(phenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-5,6a,7,8,9,9a-Hexahydro-2-methylthio-5-methyl-3-(Phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-3,4,5,6a,7,8,9,9a-Octahydro-5-methyl-4-oxo-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-2-carboxylic acid;
- cis-3,4,5,6a,7,8,9,9a-Octahydro-5-methyl-4-oxo-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-2-carboxylic acid, methyl ester;
- cis-5,6a,7,8,9,9a-Hexahydro-2-bromo-5-methyl-3-(phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)one;

- cis-5,6a,7,8,9,9a-Hexahydro-2-(methylaminosulfonyl)-5-methyl-3-(phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)one;
- cis-1-Cyclopentyl-5,6a,7,8,9,9a-hexahydro-5-methylcyclopent[4,5]imidazo[2,1-b]purin-4-(1H)one;
- cis-5,6a,7,8,9,9a-Hexahydro-3,5-bis-(phenylmethyl)cyclopent(4,5)imidazo(2,1-b)purin-4(3H)one;
- cis-6a,7,8,9,10,10a-Hexahydro-3,5-bis-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)one;
- cis-3-Cyclopentyl-5,6a,7,8,9,9a-hexahydro-5-methylcyclopent[4,5]imidazo(2,1-b)purin-4(3H)one;
- 5' -Methyl-3'-(phenylmethyl)spiro[cyclopentane-1,7-(8'H)-(3'H)imidazo[2,1-b]purin]-4-(5H)one;
- 2',5'-Dimethyl-3'-(phenylmethyl)-spiro[cyclopentane-1,7-(8'H)-(3H)imidazo[2,1-b]purin]-4-(5'H)one;
- cis-5,6a,(R)7,8,9,9a(S)-Hexahydro-5-methyl-3-(phenylmethyl)cyclopent[4,5]-imidazo(2,1-b)purin-4(3H)one;
- cis-3-Cyclopentyl-5,6a,7,8,9,9a-Hexahydro-2,5-dimethylcyclopent[4,5]imidazo-[2,1-b]purin-4(3H)one;
- 5'-Methyl-2'-trifluoromethyl-3'-(phenylmethyl)spiro{cyclo-pentane-1,7'(8'H)-(3'H)imidazo[2,1-b]purin}-4-(5'H)-one;
- 7,8-Dihydro-5,7,7-trimethyl-2-trifluoromethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one;
- (+/-)-cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2-trifluoromethyl-3-(phenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- (+/-)-6a,7,8,9,9a,10,11,11 a-Octahydro-2,5-dimethyl-3-(phenylmethyl)-3H-pentaleno[6a',1':4,5]imidazo[2,1-b]purin-4(5H)-one;
- (+)-6a,7,8,9,9a,10,11,11a-Octahydro-2,5-dimethyl-3-phenylmethyl-3H-pentaleno[6a',1':4,5]imidazo[2,1-b]purin-4(5H)-one;
- (-)-6a,7,8,9,9a,10,11,11a-Octahydro-2,5-dimethyl-3-phenylmethyl-3H-pentaleno[6a',1':4,5]Imidazo[2,1-b]purin-4(5H)-one;

- (+/-) 6a,7,8,9,9a,10,11,11a-Octahydro-2,5-dimethyl-3H-pentaleno[6a',1':4,5]-imidazo[2,1-b]purin-4(5H)-one;
- (+)-6a,7,8,9,9a,10,11,11a-Octahydro-2,5-dimethyl-3H-pentaleno[6a',1':4,5]-imidazo[2,1-b]purin-4(5H)-one;
- (-)-6a,7,8,9,9a,10,11,11a-Octahydro-2,5-dimethyl-3H-pentaleno[6a',1':4,5]-imidazo[2,1-b]purin-4(5H)-one;
- 6a,7,8,9,10,10a,11,12,13,13a-Decahydro-2,5-dimethyl-(3-phenylmethyl)-napth[1,8a-d]imidazo[2,1-b]purin-4(5H)one;
- 7(R)-Cyclohexyl-7,8-dihydro-2,5-dimethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(3H)-one;
- 7(R)-Cyclohexyl-7,8-dihydro-2,5-dimethyl-3H-imidazo[2,1-b]purin-4(5H)-one;
- 7(S)-Cyclohexyl-7,8-dihydro-2,5-dimethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(3H)-one;
- 7(S)-Cyclohexyl-7,8-dihydro-2,5-dimethyl-3H-imidazo[2,1-b]purin-4(5H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-[3-(trimethylacetoxy)methyl]-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(4-pyridylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-[2-(4-morpholinyl)-ethyl]cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-[acetoxymethyl]cyclopent-[4,5]imidazo[2.1-b]purin-4(3H)-one;
- 5,6a,7,8,9,9a-Hexahydro-2,5,6a-trimethyl-3-(phenylmethyl)cyclopent-[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5,6a-trimethyl-3-(phenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- 5,6a(S),7,8,9,9a(R)-Hexahydro-2,5,6a-trimethyl-3-(phenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one;
- cis-6a,7,8,9, 10,10a-Hexahydro-2,5,7-trimethyl-3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)-one;

- cis-5,6a,7,8,9,9a-Hexahydro-2,5,6a-trimethylcyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one; or
- cis-[6a,7,8,9,10,10a-Hexahydro-2,5,7-trimethyl-3H-benzimidazo[2,1-b]purin-4(5H)-one].

in free or salt form.

16. The method according to claim 1, wherein the PDE 1 Inhibitors for use in the methods of treatment described herein are Compounds of Formula IXa or IXb



Formula IXa



Formula IXb

or a pharmaceutically acceptable salt thereof, wherein,

q=0 or 1;

R^1 is H, cycloalkyl, alkyl, R^{23}-alkyl- or R^{26};

R^a, R^b and R^c are, independently of one another, each H, alkyl, cyoloalkyl, aryl, R^{22}-aryl- or R^{24}-alkyl-; or

R^a and R^b, together with the carbon to which they are both attached, form a 4- to 7-membered ring, and R^c is H or alkyl; or

R^a and R^c, together with the respective carbons to which they are attached, form a 4- to 7-membered ring, and R^b is H or alkyl;

(i) X is a bond;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is monohaloalkyl, polyhaloalkyl, provided that it is not trifluoromethyl, azido, cyano, oximino, cycloalkenyl, heteroaryl, R^{22}-heteroaryl- or R^{27}-alkyl-;

(ii) X is a bond;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is H, halo, —CONHR^6, —CONR^{6}R^7, —CO_2R^6, monohaloalkyl, polyhaloalkyl, azido, cyano, —C=N—OR^6, cycloalkyl, cycloalkylalkyl, R^{26}, aminosulfonyl, alkyl or R^{23}-alkyl-

(iii) X is —O— or —S—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is R^{26}, cycloalkyl cycloalkylalkyl, heterocycloalkyl, cycloalkenyl or R^{26}-alkyl-;

(iv) X is —O— or —S—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is alkyl, R^{26}, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, cycloalkenyl or R^{28}-alkyl-;

(v) X is —SO— or —SO_2—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is alkyl, R^{26}, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, cycloalkenyl or R^{28}-alkyl-;

(vi) X is —NR^8—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is $(R^{29})_p$-alkyl-, cycloalkyl, $(R^{30})_p$-cycloalkyl-, cycloalkenyl, $(R^{30})_p$-cycloalkenyl-, heterocycloalkyl or $(R^{30})_p$-heterocycloalkyl-:

(vii) X is —NR^8—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is alkyl, R^{26}, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, cycloalkenyl or R^{31}-alkyl-; or

(viii) X is —C≡C—;

Y is aryl-alkyl or R^{22}-aryl-alkyl-; and

R^2 is alkyl, R^{26}, cycloalkyl, cycloalkylalkyl or R^{23}-alkyl-;

where,

R^6 is H or R^7;

R^7 is alkyl, cycloalkyl or cycloalkylalkyl;

R^8 is heterocycloalkyl or R^6;

R^{21} is 1-6 substituents each independently selected from the group consisting of halo, hydroxy, alkoxy, phenoxy, phenyl, nitro, aminosulfonyl, cyano, monohaloalkyl, polyhaloalkyl, thiol, alkylthio, cyoloalkyl, cycloalkylalkyl, amino, alkylamino, acylamino, carboxyl, —$C(O)OR^{34}$, carboxamido, —OCF_3 and acyloxy;

R^{22} is 1-6 substituents each independently selected from the group consisting of alkyl and R^{21};

R^{23} is cycloalkoxy aryloxy, alkylthio, arylthio, cycloalkyl or R^{28};

R^{24} is cycloalkyl or R^{26};

R^{25} is hydroxy, alkoxy, amino, monoalkylamino, dialkylamino or R^{26};

R^{26} is aryl, R^{22}-aryl-, heteroaryl or R^{22}-heteroaryl-;

R^{27} is cycloalkoxy, aryloxy, alkylthio, arylthio, heteroaryl, R^{22}-heteroaryl-, cycloalkyl, heterocycloalkyl, cycloalkenyl, cycloalkylamino or heterocycloalkylamino;

R^{28} is cycloalkylamino, heterocycloalkylamino or R^{25};

R^{29} is alkoxy, cycloalkylamino, heterocycloalkylamino or R^{26};

R^{30} is halo, hydroxy, alkoxy, amino, aminosulfonyl, cyano, monohaloalkyl, polyhaloalkyl, thiol, alkylthio, alkyl, cyoloalkyl, cycloalkylalkyl or acyloxy;

R^{31} is cycloalkyl or R^{28};

R^{34} is alkyl, aryl, aralkyl and heteroaryl; and

p is 1 to 4.

17. The method according to claim 1, wherein the PDE 1 Inhibitors for use in the methods of treatment described herein are Compounds of Formula X:



Formula X

in free or a pharmaceutically acceptable salt thereof, wherein:

R_1, R_2 and R_3 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogeno, hydroxy, (di-lower alkyl)amino, 4-morpholinyl, 1-pyrrolidinyl, 1-pyrrolyl, --CF_3, --OCF_3, phenyl and methoxyphenyl; or R_1 and R_2 together are methylenedioxy; or R_1 and R_2 together with the carbon atoms to which they are attached form a benzene ring; and

R^a is hydrogen and R^b and R^c, together with the carbon atoms to which they are attached, form a saturated ring of 5 carbons; or R^a is lower alkyl, R^b is hydrogen or lower alkyl, and R^c is hydrogen; or R^a, R^b and the carbon atom to which they are attached form a saturated ring of 5-7 carbons, and R^c is hydrogen; or R^a is hydrogen, and R^b, R^c and the carbon atoms to which they are attached form a tetrahydrofuran ring; or R^a and R^b, together with the carbon atom to which they are attached, and R^b and R^c, together with the carbon atoms to which they are attached, each form a saturated ring of 5-7 carbons.

18. The method of claim 1, wherein the PDE 1 Inhibitors for use in the methods of treatment described herein are Compounds selected from:



,



,



,



,



,



,



and



in free or salt form.

19. The method according to any of the preceding claims wherein the compound inhibits phosphodiesterase-mediated hydrolysis of cGMP or cAMP.

20. The method according to any of the preceding claims wherein the PDE1 inhibitor is a PDE1B inhibitor.

21. The method according to any of the preceding claims further comprising administering a compound or compounds selected from central nervous system stimulants, modafinil, antidepressants, and gamma hydroxybutyrate, to a patient in need thereof.

22. A PDE 1 Inhibitor as described in any of claims 2-18 for use in the treatment or prophylaxis of narcolepsy.

23. Use of a PDE 1 Inhibitor as described in any of claims 2-18 in the manufacture of a medicament for the treatment or prophylaxis of narcolepsy.

24. A pharmaceutical composition comprising a PDE 1 Inhibitor as described in any of claims 2-18, in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier for use in the treatment or prophylaxis of narcolepsy.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 07/23854

A. CLASSIFICATION OF SUBJECT MATTER
IPC(8) - A01N 43/04, 43/50; A61K 31/70 (2008.01)
USPC - 514/45, 385
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
USPC: 514/45, 385

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC: 514/94,118

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
PubWEST(USPT,PGPB,EPAB,JPAB); GoogleScholar
Search Terms: phosphodiesterase, PDE, pyrazolopyrimidinone, narcolepsy narcoleptic

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2002/060428 A2 (YOUNG et al.) 8 August 2002 (08.08.2002) pg 4, ln 27-end; pg 18, ln 6-12	1-19 and 22-24
Y	US 6,969,719 B2 (ASBEROM et al.) 29 November 1995 (29.11.1995) Abstract	2-7, 11 and 14-16
Y	US 6,756,373 B1 (ALLERTON et al.) 29 June 2004 (29.06.2004) col 1, ln 35-61; col 4, ln 50-55	2-7
Y	US 5,294,612 A (BACON et al.) 15 March 1994 (15.03.1994) col 4, ln 10-33	3-5 and 7
Y	US 6,235,742 B1 (BELL et al.) 22 May 2001 (22.05.2001) Abstract	1-19 and 22-24
Y	US 5,939,419 A (TULSHIAN et al.) 17 August 1999 (17.08.1999) col 31, compound 1.4	12-13 and 17-18
A	US 5,719,283 A (BELL et al.) 17 February 1998 (17.02.1998) Abstract	1-19 and 22-24

☐ Further documents are listed in the continuation of Box C. ☐

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 January 2008 (23.01.2008)	22 APR 2008
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 07/23854

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 20-21
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.